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3-Bromopyruvate as an anticancer agent in breast cancer cell lines: exploring 
the role of monocarboxylate transporters 
Abstract  
The development of a tumor is marked by several metabolic alterations mainly at the 
glycolytic level. The Warburg effect is reflected into the ability of tumor cells to produce most of 
their energy from glycolysis even in the presence of oxygen (aerobic glycolysis), leading to an 
increased production of lactate. The monocarboxylate transporters (MCTs) play a central role in 
maintenance of high glycolytic rates allowing the efflux of lactate to extracellular environment, 
which contribute to acidic microenvironment important in the maintenance and tumor 
progression. The pyruvate analogue, 3-bromopyruvate (3-BP), whose transport can be mediated 
by MCTs, is an alkylating agent able to inhibit the action of metabolic enzymes, leading to ATP 
depletion and consequent cell death. In a previous work, our group demonstrated that 
pre-incubation of breast cancer cell lines with butyrate increased the cytotoxic effect of 3-BP, 
especially in the ones more resistant to 3-BP, by inducing localization of MCT1 in the plasma 
membrane, as well as upregulation of MCT4 expression. In the present study, we aimed to 
characterize the effect of butyrate alone or in simultaneous with 3-BP, in four breast cancer cell 
lines with different sensibilities to 3-BP and evaluated the expression of MCTs in these conditions. 
Our results showed that the four human breast cancer cell lines, namely two luminal 
subtype (ZR-75-1 and MCF-7), one basal subtype (MDA-MB-231) and one HER2+ subtype 
(SK-BR-3) presented a distinct basal expression pattern of MCTs. Butyrate induced cell death 
dependent on its concentration and also increased the expression of MCT4 but not MCT1, more 
evident in the cell lines more sensitive, namely ZR-75-1 and MCF-7. Regarding the simultaneous 
treatment, the presence of low dose of butyrate contributed to cytotoxic effect of 3-BP, while the 
high dose led to an inhibition effect in the ZR-75-1 and MCF-7 cell lines. These results were 
correlated with increased expression of MCT2 in these conditions. Higher dose of butyrate alone 
or in combination with 3-BP, increased the number of cells in G1-phase of the cell cycle in the 
cell line MDA-MB-231, sensitizing cells to the cytotoxic effect of 3-BP. Moreover, we observed that 
3-BP reduced the amount of actin in ZR-75-1. In order to understand the role of MCTs in 
response to 3-BP we started the optimization of the conditions for siRNA-mediated silencing of 
MCT1 and MCT4 in ZR-75-1, MCF-7 and SK-BR-3 cell lines. The results obtained in this study 
intend to contribute towards a better understanding of molecular mechanisms of the 3-BP action, 
and open novel therapeutic possibilities for breast cancer. 
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3-Bromopiruvato como agente anticancerígeno em linhas celulares de cancro 
da mama: explorando o papel dos transportadores de monocarboxilatos 
 
Resumo 
 
O desenvolvimento do tumor é marcado por alterações metabólicas principalmente ao 
nível da glicólise. O efeito de Warburg traduz-se na capacidade das células tumorais produzirem 
a maior parte da sua energia a partir da glicólise mesmo na presença de oxigénio (glicólise 
aeróbica), levando à produção aumentada de lactato. Os transportadores de monocarboxilatos 
(MCTs) desempenham um papel central na manutenção da elevada taxa glicolítica permitindo o 
efluxo do lactato para o meio extracelular, que contribui para o microambiente acídico 
importante na manutenção e progressão do tumor. O análogo do piruvato, 3-Bromopiruvato 
(3-BP), cujo transporte pode ser mediado por MCTs, é um agente alquilante capaz de inibir a 
ação de enzimas metabólicas, levando à depleção de ATP e consequente morte celular. Num 
trabalho anterior, o nosso grupo demonstrou que em linhas celulares de cancro da mama a 
pré-incubação com butirato aumentou o efeito citotóxico do 3-BP, especialmente na linha celular 
mais resistente, induzindo a localização do MCT1 na membrana plasmática, assim como um 
aumento da expressão do MCT4. No presente estudo, procurou-se caracterizar o efeito do 
butirato aplicado sem ou com o 3-BP em simultâneo, em quatro linhas celulares de cancro da 
mama com diferentes sensibilidades para o 3-BP, e avaliar a expressão dos MCTs nestas 
condições. 
Os resultados mostraram que as quatro linhas celulares humanas de cancro da mama, 
nomeadamente duas subtipo luminal (ZR-75-1 e MCF-7), uma subtipo basal (MDA-MB-231) e 
uma subtipo HER2+ (SK-BR-3), apresentaram um padrão de expressão basal de MCTs muito 
distinto. O butirato induziu morte celular dependente da concentração, e também aumentou a 
expressão do MCT4, mas não do MCT1, mais evidente nas linhas celulares mais sensíveis, 
nomeadamente ZR-75-1 e MCF-7. Relativamente ao tratamento simultâneo, a baixa dose de 
butirato contribuiu para o efeito citotóxico do 3-BP, enquanto que a elevada dose levou a uma 
inibição do seu efeito nas linhas celulares ZR-75-1 e MCF-7. Estes resultados foram 
correlacionados com o aumento da expressão do MCT2 nestas condições. A elevada dose de 
butirato, aplicado sozinho ou em combinação com o 3-BP, induziu um aumento do número de 
células em fase G1 do ciclo celular na linha celular MDA-MB-231, sensibilizando as células para 
o efeito do 3-BP. Além disso, observou-se que o 3-BP reduziu a quantidade de actina nas 
ZR-75-1. A fim de compreender o papel dos MCTs na resposta ao 3-BP foram optimizadas as 
condições para o silenciamento mediado por siRNA do MCT1 e MCT4 nas linhas celulares 
ZR-75-1, MCF-7 e SK-BR-3. Os resultados obtidos neste estudo pretendem contribuir para uma 
melhor compreensão dos mecanismos moleculares de ação do 3-BP, e abrir novas 
possibilidades terapêuticas para o cancro da mama. 
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1.1. Hallmarks of cancer 
 
Normal cells from living organisms establish a network that allows them to function, 
proliferate and die in a balanced environment. Several factors can contribute to the imbalance of 
the system such as alterations in environmental factors (e.g. radiation, chemical) and 
accumulation of genetic mutations in somatic cells (Pharoah, Dunning et al. 2004). These 
alterations can induce damage in DNA that can escape to the DNA repair mechanisms and lead 
to mutations and possibly disease. Neoplasia results from an uncontrolled cell proliferation that 
depends on the capability of malignant cells to invade surrounding tissues or metastasize to 
distant areas of the body (Hanahan and Weinberg 2000).  
Carcinogenesis is a multifactorial and a multistep process that requires the acquisition of 
many biological capabilities in evolution of a normal cell to a malignant state (Hanahan and 
Weinberg 2000). Most of the alterations observed during carcinogenesis have been postulated as 
hallmarks of cancer and comprise alterations at molecular, biochemical and functional level. 
These alterations result in a particular cellular behavior that allow cancer cells limitless replicative 
potential, which results in an exponential growth by activation of telomerase; capacity to escape 
programmed cell death; sustained proliferative signaling by activation of oncogenes such as RAS 
and BRAF genes; insensitivity to growth-inhibitory signals by inactivation of tumor suppressor 
genes, such as p53, and activation of invasion/metastasis by loss of E-cadherin (Hanahan and 
Weinberg 2000). Moreover, cancer cells can induce angiogenesis leading to the formation of new 
blood vessels from an avascular system in a tumor cell mass induced by vascular endothelial 
growth factor (VEGF). Neovascularization is essential to cancer cells survival allowing the 
availability of oxygen and nutrients, as well as the release of cellular residual metabolites and 
carbon dioxide (Hanahan and Weinberg 2000). 
Recently were proposed new hallmarks important for carcinogenesis, such as the 
inflammatory microenvironment, genome instability leading to increase the genetic alterations, 
the ability to escape immune system and the reprogramming of cellular energy metabolism 
(Hanahan and Weinberg 2011) (Figure 1). The first two new capabilities, referred as enabling 
characteristics, contribute to tumor progression by the accumulation of mutations and by 
inducing an inflammatory response. Finally, the last two capabilities named emerging hallmarks 
have received some attention given the importance of cancer cell metabolism in proliferation and 
tumor progression (Hanahan and Weinberg 2011). 
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The interaction of each one of the ten hallmarks in the tumor context provides favorable 
conditions to accelerate tumorigenesis by promoting proliferation, progression and resistance to 
defense mechanisms and, therefore leading to a malignant phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Integrative view of the ten hallmarks of cancer (Hanahan and Weinberg 2011). 
 
 
1.2. Reprogramming the energy metabolism in cancer cells 
 
Similar to normal cells the metabolism of cancer cells is essential for cell maintenance and 
proliferation (Vander Heiden, Cantley et al. 2009). Most cancer cells exhibit a peculiar high 
glycolytic metabolism even in the presence of oxygen which allows adaptation to intermittent 
hypoxia conditions, higher proliferative rates and resistance to oxidative damages induced by 
oxidative phosphorylation. Moreover, the end-product of “aerobic glycolysis”, lactate is important 
to create an extracellular acidic environment that favors the maintenance and progression of the 
tumor cell mass. 
 
 
 1.2.1.  Warburg effect in cancer cells 
 
The survival of multicellular organisms requires a constant supply of nutrients. In 
mammals, cell proliferation is regulated by growth factors that control the uptake of nutrients 
from the extracellular environment (Vander Heiden, Cantley et al. 2009). 
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Among all the nutrients, glucose occupies a central position in cell metabolism both as 
energy source and as a versatile carbon precursor for biosynthetic reactions. Glycolysis, allows 
the extraction of energy retained in the six-carbon glucose molecule by its oxidation into two 
three-carbon molecules of pyruvate. In glucose metabolism are involved several enzymes that 
participate in a series of degradation reactions (catabolic reactions) generating two molecules of 
NADH (nicotinamide adenine dinucleotide (NAD+) reduced), two molecules of adenosine 
triphosphate (ATP) and two molecules of pyruvate per molecule of glucose. 
In aerobic conditions, most differentiated tissues acquire cellular energy through the 
oxidative phosphorylation (OXPHOS), which occurs in the mitochondria (Figure 2). In OXPHOS, 
pyruvate is completely oxidized to carbon dioxide through the enzymes of the tricarboxylic acid 
(TCA) cycle associated to maximal ATP production through the respiratory chain in the 
mitochondria. The free energy resulting from this process is driven to ATP synthasome (ATP 
Synthase/Pi Carrier/Adenine Nucleotide Carrier complex) to generate ATP from ADP and 
inorganic phosphate (Pi) in the presence of Mg2+. This process occurs exclusively in aerobic 
conditions because oxygen is the final electron acceptor of the respiratory chain. In the absence 
of oxygen (anoxia) or under low oxygen conditions (hypoxia), differentiated cells are unable to 
support OXPHOS therefore pyruvate is converted to lactate via lactate fermentation in the cytosol 
(Figure 2). In anaerobic metabolism, pyruvate is reduced to lactate by lactate dehydrogenase 
isoform A (LDHA), accepting electrons from NADH and regenerating NAD+ needed to maintain 
glycolysis (Munoz-Pinedo, El Mjiyad et al. 2012). The lactate formed is secreted into the 
extracellular environment by monocarboxylate transporters (MCTs) (Gatenby and Gillies 2004). 
The energetic yield of glucose metabolism via OXPHOS generates 36 molecules ATP per 
molecule glucose, whereas lactate fermentation generates only 2 molecules ATP per molecule 
glucose (Vander Heiden, Cantley et al. 2009). According to the energetic yield, the presence of 
adequate oxygen levels inhibits lactate fermentation and the glucose metabolism is driven to 
OXPHOS which is the process energetically more efficient. This metabolic shift was first 
demonstrated by Louis Pasteur, who observed in yeast cells reduced fermentation of glucose in 
the presence of oxygen (Pasteur effect) (Racker 1974). 
In contrast to normal differentiated tissues, most cancer cells rely more on glycolysis for 
ATP production independently on the oxygen availability in the extracellular microenvironment 
(Figure 2). The high glycolytic rates of cancer cells even in the presence of oxygen was first 
demonstrated by Otto Warburg (Warburg 1956). The first explanation of this phenomenon termed 
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Warburg effect or “aerobic glycolysis” was given by him who suggested that irreversible damage 
in the mitochondrial function in cancer cells limited the oxidative phosphorylation and therefore 
glucose metabolism occurred exclusively by the glycolytic pathway and it was causally involved in 
the development of tumors (Warburg 1956). However, it was later found that mitochondrial 
function is not altered in all cancer cells that exhibits Warburg effect and this would be not the 
reason for the typical phenotype of cancer cells (Schulze and Harris 2012). Recent studies have 
shown that glycolytic switch in cancer cells is also promoted by activation of oncogenes as Ras 
and inhibited by tumor suppressor genes, such as pVHL, indicating that it is intrinsically 
associated to carcinogenesis process (Koppenol, Bounds et al. 2011). 
 
 
 
Figure 2. Schematic representation of glucose metabolism in differentiated tissues (left panel), 
normal proliferative tissues and tumor cells (right panel). In differentiated tissue the presence or absence 
of oxygen determine two different pathways for glucose metabolism: oxidative phosphorylation and 
anaerobic glycolysis, respectively. In normal proliferative tissues and tumor cells, glucose metabolism is 
mainly driven to lactate fermentation even in the presence of oxygen (Warburg effect or aerobic glycolysis) 
(Vander Heiden, Cantley et al. 2009). 
 
 
The metabolic reprogramming typical of cancer cells raises many questions: Why cancer 
cells produce energy by glycolysis under aerobic conditions? What are the advantages of 
glycolysis for cancer cells? Understanding the role of cell-environment interactions in tumor 
evolution is the key for these answers. 
The hyperproliferative state of cancer cells leads to a development from a normal 
epithelium to an interstitial neoplasia characterized by uncontrolled cell proliferation that 
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progresses to a carcinoma in situ (Figure 3). In an intratumoral hypoxic environment, cancer cells 
achieved the oxygen diffusion limit which induces one of the two cell responses: adaptation to 
anaerobic glycolysis for ATP production which allows cells to survive or cell death. The metabolic 
adapted cancer cells acquire the ability of motility that leads to basement membrane breakdown 
and consequent access to blood vessels and lymphatic vasculature progressing the carcinoma in 
situ to an invasive state (Gatenby and Gillies 2004). However, some cancer cells remain 
glycolytic even oxygen availability is restored in oxygenated regions, producing most of ATP by 
glycolysis (Mathupala, Colen et al. 2007). 
 
 
Figure 3. Schematic representation of the cell-microenvironment interactions associated with the 
carcinogenesis process. Normal epithelial (grey), hyperproliferative (pink), hypoxic (blue), glycolytic (green) 
and motile cells (yellow) (Gatenby and Gillies 2004). 
 
 
The rapid proliferation of cancer cells requires cellular energy in form of ATP obtained by 
glycolysis and supported by high increased of glucose uptake (Vander Heiden, Cantley et al. 
2009). The upregulation of glycolysis metabolism generates metabolic intermediates that can be 
converted into anabolic reactions, such as synthesis of nucleic acids, lipids and proteins, 
increasing the availability of important biosynthetic precursors for cell growth and proliferation 
(Figure 4). For instance, the metabolism of glycolytic intermediate glucose-6-phosphate (G6P) 
through the pentose phosphate pathway (PPP) generates ribose-5-phosphate (Rib-5-P), an 
important intermediate in nucleotide biosynthesis. The oxidative pathway of PPP can also 
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produce nicotinamide adenine dinucleotide phosphate (NADPH), which supplies reducing 
equivalents for both nucleotide and fatty acid biosynthesis (Jones and Thompson 2009). Cancer 
cells can also take advantage of high glycolytic rates since the lactate efflux creates an 
extracellular acidic micro-environment which favors the process of invasion/metastasis, by 
activation of proteases that are involved in degradation of the extracellular matrix and basement 
membranes, such as metalloproteinases (MMP), (Pedersen 2007; Kroemer and Pouyssegur 
2008), activation of proteins as hyaluronan and its receptor CD44, which are molecules involved 
in invasion and metastization (Stern, Shuster et al. 2002) and also contributes to the evasion 
from the immune system by blocking the glycolytic pathway of lymphocytes T (Frauwirth and 
Thompson 2004; Fischer, Hoffmann et al. 2007). Moreover, the exported lactate promotes 
angiogenesis by increasing vascular endothelial growth factor (VEGF) levels associated with the 
tumor aggressiveness (Hirschhaeuser, Sattler et al. 2011). On the other hand, the residual rate 
of OXPHOS metabolism provides protection to DNA damaging induced by reactive oxygen species 
(ROS) mainly produced in mitochondrial respiratory chain by complex I and III (Kroemer and 
Pouyssegur 2008). The “aerobic glycolysis” of cancer cells allows the metabolism of glucose in 
intermittent hypoxia conditions, which is important for the maintaining of the metabolism under 
different oxygen levels (Lopez-Lazaro 2008). 
The interest in the peculiar metabolism of cancer cells led to the discovery of an 
hexokinase isoform which is overexpressed in cancer cells (Nakashima, Mangan et al. 1986). 
The enzyme hexokinase II (HK II) catalyzes the formation of glucose-6-phosphate (G6P) from 
glucose and ATP in the first irreversible step of the glycolysis (Wilson 1995; Wilson 1997). This 
hexokinase isoform is associated with outer mitochondrial membrane via Voltage Dependent 
Anion Channel Protein (VDAC) allowing both direct access to intramitochondrial ATP synthetized 
in the ATP synthasome to phosphorylate glucose, and protection from feedback inhibition by its 
product G6P (Nakashima, Mangan et al. 1986). The interaction of HK II with the complex ATP 
synthasome also keeps VDAC in the open state which counteracts with outer mitochondrial 
membrane (OMM) permeabilization involved in intrinsic pathway of apoptosis blocking binding 
sites for pro-apoptotic Bcl-2 family proteins in the OMM (Gogvadze, Zhivotovsky et al. 2010). 
The high increase of glucose uptake by cancer cells is the basis for imaging technique that 
allows detection of tumors. In this detection system, namely positron emission tomography 
(PET), is used a glucose analogue tracer 18fluorodeoxyglucose (FDG) which is phosphorylated by 
hexokinase into a non-metabolizable product that accumulates in highly glycolytic cancer cells. 
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The accumulation of the radioactive glucose analogue is detected by [18F]-fluorodeoxyglucose 
positron emission tomography (18FDG-PET) (Gatenby and Gillies 2004). FDG-PET imaging is used 
as a non-invasive method to cancer diagnosis, as well as to monitor therapeutic response, and 
also allows the quantification of glucose uptake that is correlated with tumor aggressiveness 
(Gatenby and Gillies 2004). However, the sensitivity of FDG-PET imaging is lowered for tumors 
with small size (<0.8 cm3), and specificity is lowered because immune cells are also capable to 
trapped FDG (Gatenby and Gillies 2004). Nuclear magnetic resonance (NMR) spectroscopy has 
been explored as a non-invasive method for the detection of selected metabolites such as 
glutamine and acetate in tumors in vivo and can provide an insight into metabolic response to 
therapy (Schulze and Harris 2012). 
Although glycolysis is the mainly pathway responsible for ATP production in cancer cells, 
there are other metabolic pathways upregulated, such as glutaminolysis, lipid synthesis, ketone 
oxidation and serinolysis (Figure 4) (Vander Heiden, Cantley et al. 2009). Glycolysis and 
glutaminolysis are the most important pathways in the context of tumor. Glutaminolysis is an 
alternative pathway for ATP production upregulated in MYC-transformed cells (Wise, DeBerardinis 
et al. 2008). In this pathway, glutamine is converted to glutamate by glutaminase enzyme and 
generates intermediates of the TCA cycle redirected into biosynthetic reactions important to cell 
growth and proliferation (Vander Heiden, Cantley et al. 2009). 
 
 
Figure 4. Schematic overview of cancer cells metabolism (Schulze and Harris 2012). 
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1.2.2. Molecular mechanisms driving Warburg effect 
 
Many of the mutations observed in tumors are related to metabolism control (Figure 5) 
(Vogelstein and Kinzler 2004). The high glycolytic phenotype of cancer cells can be driven by 
alterations in signaling pathways that include transcription factors, such as hypoxia inducible 
factor (HIF) and MYC, and kinases such as mTOR and phosphatidylinositol 3-kinase (PI3K) 
(Kroemer and Pouyssegur 2008). 
A principal regulator of cell metabolism is the PI3K, a lipid kinase that regulates the 
phosphorylation levels of phosphatidylinositol (PIP3) at the plasma membrane (Jones and 
Thompson 2009). Activation of PI3K leads to the activation of downstream effectors including 
mammalian target of rapamycin (mTOR) and the protein kinase B (Akt) that regulate metabolic 
activities involved in cellular biosynthesis (Jones and Thompson 2009). In normal cells, PI3K 
activation is high controlled by dephosphorylation of PIP3 by the phosphatase PTEN, a tumor 
suppressor. The pathway is deregulated in cancer through a diversity of mechanisms, including 
PTEN loss or activating mutations in PI3K (Jones and Thompson 2009). PI3K/Akt signaling 
promotes glycolysis through Akt-dependent stimulation by upregulation and membrane 
localization of glucose transporters (GLUT1 and GLUT4); activity and mitochondrial localization of 
hexokinase and phosphofructokinase; and enhanced protein translation through Akt-dependent 
mTOR activation (Edinger and Thompson 2002). 
The survival of cancer cells in hypoxia is achieved by activation of the transcription factor 
hypoxia inducible factor-1 (HIF-1), a heterodimer composed of a constitutive HIF-1β subunit and 
a labile HIF-1α subunit (Tennant, Duran et al. 2010). Under anoxia conditions, the activation of 
HIF-1α increases the upregulation of genes involved in glycolysis including glucose transporter 1 
and 3 (GLUT 1 and GLUT3), Hexokinase II (HK II, which catalyze the initial step of glycolysis), 
and lactate dehydrogenase A (LDHA), as well as involved in angiogenesis as VEGF and 
hematopoietic factors (erythropoietin) that accelerate tumorigenesis (Brahimi-Horn, Chiche et al. 
2007; Semenza 2008). HIF1 also promotes the induction of pyruvate dehydrogenase kinase 1 
(PDK1), a negative regulator of pyruvate dehydrogenase (PDH) that catalyzes the conversion of 
pyruvate to acetyl-CoA. This upregulation reduces electron flux through OXPHOS and 
subsequently reduces oxidative stress resulted from mitochondrial metabolism (Semenza 2008). 
Oncogenic c-Myc is a regulator of metabolic pathways essential for tumor progression, 
such as glycolysis and glutaminolysis (Dang, Kim et al. 2008). MYC promotes aerobic glycolysis 
Introduction 
11 
 
by enhanced the expression of GLUT1 and LDHA (Shim, Dolde et al. 1997). The transcription 
factor MYC is also important in regulation of proliferation and cell cycle entry (Schulze and Harris 
2012). 
Inactivation of a tumor suppressor gene p53 also promotes glycolysis in cancer cells by 
both decreased a glycolysis inhibitor TIGAR (TP53-induced glycolysis and apoptosis regulator) 
expression, and the synthesis of the protein cytochrome c oxidase 2 (SCO2) required for the 
correct assembly of the cytochrome c oxidase (COX) complex of the electron chain in the 
mitochondria. The loss of p53 protein activity also increases glucose uptake and HIF-1 levels 
(Vander Heiden, Cantley et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3. Monocarboxylate transporters 
 
Lactate is the monocarboxylic acid that can be formed as end-product of glycolysis and its 
intracellular accumulation results in acidification of the cytosol and inhibition of 
phospho-fructokinase-1 (PFK-1) and consequently glycolysis (Halestrap and Price 1999). 
Therefore, the transmembrane transport of monocarboxylic acids is an essential mechanism for 
pH homeostasis in mammalian cells, and is catalyzed by monocarboxylate transporters (MCTs) 
(Halestrap and Price 1999). The efflux of lactate is particularly important for high glycolytic cells 
Figure 5. Schematic representation of the molecular mechanisms driven the Warburg effect in 
cancer cells (Kroemer and Pouyssegur 2008). 
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such as most cancer cells, white and red blood cells, and tissue skeletal muscle (Merezhinskaya 
and Fishbein 2009). 
Actually, are described fourteen human MCT members belonging to the MCTs family 
encoded by the SLC16 gene family of solute carriers (Table I) (Halestrap and Meredith 2004; 
Halestrap and Wilson 2012). The predicted topology of these transporters showed 12 alpha-
helical transmembrane domains (TMDs) with an intracellular N- and C-terminus and a large 
intracellular loop between TMDs 6 and 7 (Poole, Sansom et al. 1996). Based on amino acid 
sequence and functional similarities, the heterogenic MCTs family can be divided into three main 
clusters, where MCT1-4 cluster is responsible for the H+-linked transport of endogenous 
monocarboxylic acids, such as pyruvate, lactate and ketone bodies across the plasma membrane 
with different tissue distribution, regulation and substrate/inhibitor affinity (Pinheiro, Longatto-
Filho et al. 2012). In MCT1-4 cluster, both influx and efflux of monocarboxylates are 
cotransporter couple to protons in a equimolar manner by a simport mechanism according to 
substrate concentration and pH gradient between intracellular and extracellular environment 
(Halestrap and Wilson 2012). MCTs 5-7, 9 and 11-14 are described as orphan transporters 
whose substrates are unknown and their functional role is not characterized (Morris and Felmlee 
2008). MCT8 and MCT10 have a wide tissue distribution and are thyroid hormones 
triiodothyronine (T3)/thyroxine (T4) and aromatic aminoacids transporters, respectively. Both 
MCT8 and MCT10 isoforms have been demonstrated to transport their substrates in a H+- and 
Na+- independent manner (Morris and Felmlee 2008) 
Recently has been described two members of Na+-linked monocarboxylate transporters 
(SMCTs) solute carrier transporter family, the SLC5A8 (SMCT1) and SLC5A12 (SMCT2) present 
in the plasma membrane able to transport monocarboxylates across the plasma membrane (Li, 
Myeroff et al. 2003). SMCTs mediate the active transport of a variety of monocarboxylic acids 
against its chemical gradient using the energy released by the translocation of Na+ in favor of its 
concentration gradient (Miyauchi, Gopal et al. 2004). These transporters demonstrate a more 
restricted distribution in thyroid gland, kidney, colon, retina and brain, while MCTs show a more 
ubiquitous distribution (Paroder, Spencer et al. 2006; Ganapathy, Thangaraju et al. 2008; 
Thangaraju, Cresci et al. 2008). In the intestine SMCT1 transporter mediates the uptake of 
butyrate from the lumen into colonocytes (Gupta, Martin et al. 2006; Ganapathy, Thangaraju et 
al. 2008; Thangaraju, Cresci et al. 2008). SMCT1 also function as a tumor suppressor gene in 
both gliomas and colon cancer (Li, Myeroff et al. 2003). 
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Table I. The human Monocarboxylate Transporter Family (adapted from Halestrap and Meredith 
2004; Morris and Felmlee 2008). T3 – triiodothyronine; T4 – thyroxine; CPE – choroid plexus epithelium; RPE – 
retinal pigment epithelium 
MCT  Human gene 
name 
Substrates Tissue distribution Transport 
mechanism 
MCT1 SLC16A1 Lactate, pyruvate, 
ketone bodies 
Ubiquitous H+ cotransporter    
exchanger 
MCT2 SLC16A7 Lactate, pyruvate, 
ketone bodies 
Kidney, brain H+ cotransporter 
MCT3 SLC16A8 Lactate RPE, CPE H+ cotransporter 
MCT4 SLC16A3 Lactate, pyruvate, 
ketone bodies 
Skeletal muscle, heart, lung, 
chondrocytes, leucocytes, 
testis, placenta 
H+ cotransporter 
MCT5 SLC16A4 Orphan Brain, muscle, liver, kidney, 
lung, ovary, placenta, heart 
Orphan 
MCT6 SLC16A5 Orphan Kidney, muscle, brain, heart, 
pancreas, prostate, lung, 
placenta 
Facilitated diffusion 
MCT7 SLC16A6 Orphan Brain, pancreas, muscle Orphan 
MCT8 SLC16A2 T3, T4 Liver, heart, brain, thymus, 
intestine, ovary, prostate, 
pancreas, placenta 
Orphan 
MCT9 SLC16A9 Orphan Endometrium, testis, ovary, 
breast, brain, kidney, adrenal, 
RPE 
Orphan 
MCT10 SLC16A10 Aromatic amino 
acids 
Kidney, intestine, muscle, 
placenta, heart 
Facilitated 
diffusion/exchanger 
MCT11 SLC16A11 Orphan Skin, lung, ovary, breast, 
pancreas, RPE, CPE 
Orphan 
MCT12 SLC16A12 Orphan Kidney Orphan 
MCT13 SLC16A13 Orphan Breast, bone marrow Orphan 
MCT14 SLC16A14 Orphan Brain, heart, ovary, breast, 
lung, pancreas, RPE, CPE 
Orphan 
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1.3.1. Function and expression of MCT family 
 
 MCT1 has an ubiquitous distribution and catalyzes the cellular uptake and efflux of 
monocarboxylates such as pyruvate (Km 0.6-1 mM), L-lactate (Km 2.2-4.5 mM), proprionate (Km 
1.5 mM), acetate (Km 3.7 mM), acetoacetate (Km 5.5 mM), L-β-hydroxybutyrate (Km 8.1-11.4 mM) 
and D-β-hydroxybutyrate (Km 8.1-10.1 mM) (Halestrap and Meredith 2004; Pinheiro, Longatto-
Filho et al. 2012). MCT1 is mostly responsible for lactate uptake for oxidation in red skeletal 
muscles and heart or efflux in glycolytic cells, such as erythrocytes, according to the substrate 
concentration and pH gradient (Halestrap and Meredith 2004). MCT1 isoform is also associated 
with the transport of butyrate and proprionate in human colonocytes (Cuff, Lambert et al. 2002). 
MCT1 function as a proton-dependent cotransporter/exchanger and transport across the 
membrane occurs by ordered sequential binding with association of a proton followed by lactate 
binding (Juel and Halestrap 1999). The isoform MCT2 was characterized by heterologous 
expression in Xenopus laevis oocytes and is expressed in gluconeogenic tissues (kidney, liver and 
brain) where catalyzes with higher affinity the uptake of L-lactate (Km 0.7 mM), D-β-
hydroxybutyrate (Km 1.2 mM), pyruvate (Km 0.08 mM) and acetoacetate (Km 0.8 mM) than MCT1 
(Broer, Broer et al. 1999; Pinheiro, Longatto-Filho et al. 2012). MCT3 has a very restricted 
distribution in the basolateral membrane of the retinal pigment epithelium (RPE) and the choroid 
plexus epithelia (CPE), and catalyzes the L-lactate export in the retina (Bergersen, Johannsson et 
al. 1999). Finally, the isoform MCT4 is predominantly expressed in highly glycolytic cells such as 
white blood cells (leucocytes), white skeletal muscle fibers and astrocytes, exhibiting the highest 
Km values for most substrates that MCT1 and MCT3, such as L-lactate (km 28.0-34.0) and 
pyruvate (Km 153.0) (Dimmer, Friedrich et al. 2000; Pinheiro, Longatto-Filho et al. 2012). The 
physiologic function of MCT4 is the efflux of lactate of glycolytic cells (Halestrap and Meredith 
2004).  
Recent studies have shown that MCTs1-4 are heteromeric transporters composed of an 
catalytic α-subunit (MCT) and an accessory β-subunit (CD147) (Philp, Ochrietor et al. 2003). The 
expression and functional activity of MCTs1-4 is associated with ancillary proteins that are 
involved in correct trafficking and anchoring to the plasma membrane. MCT1, 3 and 4 require 
association with the mature glycosylated form of CD147 protein also known as Extracellular 
Matrix Metalloproteinase Inducer (EMMPRIN) or basigin (Kirk, Wilson et al. 2000; Gallagher, 
Castorino et al. 2007; Pinheiro, Reis et al. 2010) in the endoplasmatic reticulum, while MCT2 
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isoform requires the association with integral membrane glycoprotein gp70 or EMBIGIN 
(Gallagher, Castorino et al. 2007). MCT4 expression regulates the maturation of CD147 in a high 
invasive breast cancer cell line MDA-MB-231, supporting the high glycolytic rates and consequent 
increase in efflux of lactate (Gallagher, Castorino et al. 2007). 
 
 
1.3.2. Genetic regulation of MCT family 
 
The regulation of MCTs expression can be driven by a variety of stimuli including 
hormones, exercise and monocarboxylic acids like butyrate and lactate (Kennedy and Dewhirst 
2010). MCTs expression undergoes transcriptional, post-transcriptional and post-translational 
regulation and appears to be regulated in a tissue-specific manner (Morris and Felmlee 2008). 
Several studies have shown that in skeletal muscle MCT1 levels increase in response to chronic 
stimulation (e.g. chronic electrical stimulation) or exercise in rats and humans mediated by 
calcium and cyclic adenosine monophosphate (AMP) that activate calcineurin and AMP-activated 
protein kinase (AMPK) (Coles, Litt et al. 2004; Halestrap and Wilson 2012). Thyroid-stimulating 
hormone has also been associated with the upregulation of MCT1 and MCT4 expression in 
skeletal muscle (Halestrap and Wilson 2012). Treatment with testosterone resulted in an 
increase of MCT1 protein expression without alteration in MCT1 mRNA level suggesting an post-
transcriptional regulation (Enoki, Yoshida et al. 2006). Others studies have shown that butyrate 
stimulate MCT1 promoter activity in both colon cancer cell line Caco-2 and colonic epithelial cell 
line AA/C1 via NF-κB pathway suggesting a transcriptional regulation mechanism (Cuff, Lambert 
et al. 2002; Borthakur, Saksena et al. 2008). Recently were suggested that GPR109A, a luminal 
short-chain fatty acid (SCFA) sensor, mediates the effects of SCFA substrates in MCT1 
membrane localization and function (Borthakur, Priyamvada et al. 2012). High concentrations of 
lactate have been reported to increase MCT1 mRNA and protein levels in L6 myoblasts cells via 
NF-κB pathway (Hashimoto, Hussien et al. 2007). Trichostatin A (TSA), a histone deacetylase 
(HDAC) inhibitor can also induce the activity of MCT1 promoter in human intestinal epithelial 
cells (Borthakur, Saksena et al. 2008). Post-translational regulation of MCT1 by microRNAs has 
also been observed were miR-29a and miR-29b contribute to silence MCT1 expression in 
pancreatic β-cell-specific (Pullen, da Silva Xavier et al. 2011) and miR-124, a microRNA in the 
mammalian nervous system, regulates MCT1 expression in medullobastoma cells (Li, Pang et al. 
2009). MCT1 gene is reported to be hypermethylated (Hussien and Brooks 2011). 
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 The isoform MCT2 has been reported to be regulated by post-translational mechanisms 
(Halestrap and Wilson 2012). In brain, MCT2 expression is enhanced by noradrenaline, insulin 
and insulin like growth factor 1 (IGF-1) by translational activation (Halestrap and Wilson 2012). 
Obesity has also been associated with the upregulation of MCT2 mRNA expression levels in the 
brain of a rat OVX+E2 model (Matsuyama, Ohkura et al. 2009). 
MCT4 is mainly upregulated by hypoxia conditions through a HIF-1α-dependent 
mechanism, which is in accordance with the role of this transporter in lactate export from 
glycolytic cells (Ullah, Davies et al. 2006). Butyrate has also reported to increase the expression 
of MCT4 and the localization of MCT1 at the plasma membrane in the human breast cancer cell 
line SK-BR-3 (Queiros, Preto et al. 2012). MCT4 silencing is achieved by promoter methylation 
(Huang, Plass et al. 2011). 
 
 
1.3.3. The role of MCTs in cancer 
 
High levels of MCTs expression have been associated with carcinogenesis given the 
increase of lactate production due to Warburg effect (Pinheiro, Longatto-Filho et al. 2008; 
Pinheiro, Albergaria et al. 2010). The efflux and influx of lactate is mainly mediated by MCT4 and 
MCT1 isoforms, respectively (Semenza 2008). The presence of MCT4 in the plasma membrane 
of cancer cells plays a dual function allowing the efflux of intracellular lactate and pH regulation 
since the efflux of lactate is coupled to the output of a proton, important to prevent intracellular 
acidification and consequently apoptosis (Figure 6) (Pinheiro, Longatto-Filho et al. 2012). The 
maintenance of an appropriate intracellular pH is also ensured by others pH regulatory systems 
in the plasma membrane, such as Na+/H+ exchanger (NHE) family, carbonic anhydrase 9 (CA9) 
and anion exchanger 1 (AE1) (Chiche, Brahimi-Horn et al. 2010). 
MCT isoforms are differently upregulated in tumors including colon cancinoma, lung 
cancer, high grade gliomas, breast cancer, prostate cancer and gastric adenocarcinomas 
(Pinheiro, Longatto-Filho et al. 2012). MCT1 is upregulated in breast cancer (Pinheiro, Albergaria 
et al. 2010), colorectal (Pinheiro, Longatto-Filho et al. 2008) and cervical cancer (Pinheiro, 
Longatto-Filho et al. 2008) associated to poor prognosis. MCT4 is upregulated in cervical 
(Pinheiro, Longatto-Filho et al. 2008), colorectal (Pinheiro, Longatto-Filho et al. 2008) and 
prostate cancer (Pertega-Gomes, Vizcaino et al. 2011) and downregulated in gastric cancer 
(Pinheiro, Longatto-Filho et al. 2009). In a particular aggressive subtype of breast cancer (basal-
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like) were observed high expression of MCT1 in the cytosol and in the plasma membrane 
compared to normal breast epithelium (Pinheiro, Albergaria et al. 2010; Pinheiro, Reis et al. 
2010). Moreover, the expression of MCT2 was only present in the cytoplasm at similar levels to 
normal tissue (Pinheiro, Reis et al. 2010) and MCT4 showed a significant increase in cytoplasm 
expression compared to normal epithelium (Pinheiro, Albergaria et al. 2010) with no differences 
in plasma membrane expression. In fact, this study concluded that the high expression of MCT1 
alone or in co-expression with CD147 is associated with tumor aggressiveness in breast cancer 
(Pinheiro, Albergaria et al. 2010). 
 
 
 
Figure 6. Role of MCTs in cancer cells metabolism (Chiche, Brahimi-Horn et al. 2010). 
 
 
1.4. Metabolic targeting strategies for cancer therapy 
 
 Since metabolic phenotype of cancer cells is the basis for several mechanisms of tumor 
resistance to traditional therapy it had been explored several anticancer strategies targeting 
tumor metabolism. Metabolic strategies include indirect targets that consist in signaling pathways 
that regulates cellular metabolism altered in cancer, and direct targets such as metabolic 
enzymes (Tennant, Duran et al. 2010) (Figure 7). 
The first antimetabolites were designed to inhibiting DNA synthesis. These drugs include 5-
fluorouracil (5-FU) and cytarabine (Ara-C) that target the final stages of nucleotide synthesis 
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pathway, leading to incomplete DNA synthesis and cell death unspecific to cancer cells (Ewald, 
Sampath et al. 2008). 
The aberrant glycolytic phenotype of cancer cells has been explored as a target for direct 
inhibitors with agents targeting key enzymes of this metabolic pathway (Pelicano, Martin et al. 
2006; Tennant, Duran et al. 2010). Glucose transporter 1 (GLUT1) overexpressed in cancer 
cells, is a target for the agent phloretin (Cao, Fang et al. 2007) with promise results in cell growth 
inhibition in vitro (Devi and Das 1993) and in vivo (Nelson and Falk 1993). The first glycolytic 
enzyme, hexokinase, can be inhibited by both lonidamine and a glucose analog 2-deoxyglucose, 
currently in clinical trials in combination with others chemotherapeutic agents (Tennant, Duran et 
al. 2010). Another glycolytic inhibitor is Imatinib or Gleevec that limits hexokinase and glucose-6-
phosphate dehydrogenase (G6PD) activity in leukemia cells (Boren, Cascante et al. 2001; 
Gottschalk, Anderson et al. 2004). The final enzyme of glycolytic pathway is pyruvate kinase (PK) 
which converts phosphoenolpyruvate (PEP) into pyruvate and an inhibitor of PK, termed TLN-232 
has been used in Phase II clinical trials (Tennant, Duran et al. 2010). In lactate fermentation, 
pyruvate is reduced to lactate by lactate dehydrogenase (LDHA) and pyruvate dehydrogenase 
kinase 1 (PDHK1) regulates the activity of pyruvate dehydrogenase (PDH) complex. PDHK1 is 
inhibited by dichloroacetate (DCA) which increased PDH activity and promote switch from 
glycolysis to OXPHOS reacting mitochondrial function and generation of free radicals which were 
toxic to tumor growth. Although DCA is not a specific inhibitor for cancer cells (Stockwin, Yu et al. 
2010) it induces a decrease in tumor proliferation (Bonnet, Archer et al. 2007). 
Several small molecules are known to inhibit the function of MCTs important to support 
glycolytic metabolism by exporting lactate. MCTs inhibitors can be group into three categories: (i) 
bulky or aromatic monocarboxylates that act as competitive inhibitors, such as phenyl-pyruvate 
α-cyano-4-hydroxycinnamate (CHC) (Halestrap 1976); (ii) amphiphilic compounds as flavoniods 
(quercetin and phloretin) and anion exchanger (AE) inhibitors, such as 5-nitro-2-(3-phenyl-
propylamino)-benzoate (NPPB) (Halestrap and Meredith 2004); (iii) stilbene disulphonates as 
4,4’-diisothiocyanostilbene-2,2’-disulphonate (DIDS) (Poole and Halestrap 1991). These inhibitors 
are not specific for one MCT isoform, for instance CHC is a potent inhibitor of MCT1 but can also 
inhibit MCT2 (Halestrap and Price 1999). Recently, AstraZeneca developed a specific and high 
affinity inhibitor for MCT1 (AR-C155858) that is a potent immunosuppressive drug inhibiting T 
lymphocyte proliferation and were subsequently shown to bind to MCT1 and MCT2, but not 
MCT4 in in vitro and in vivo (Murray, Hutchinson et al. 2005). The inhibition of MCT1 occurs by 
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binding to intracellular site involving transmembrane helices 7-10 (Ovens, Davies et al. 2010) 
and MCT2 inhibition is modulated by association to ancillary protein (Ovens, Manoharan et al. 
2010). 
MCTs have been also explored as potential gateways to drug delivery particularly drugs 
with a carboxyl group in their chemical structure (Halestrap and Price 1999; Enerson and Drewes 
2003). 3-bromopyruvate (3-BP) has been further explored due to it potential as a metabolic 
inhibitor that inhibits energy production in form of ATP at both glycolysis and oxidative 
phosphorylation levels. Animal models showed that 3-BP has been efficient in eradication of 
tumors of advanced liver cancers in vivo when the compound was delivery by local infusion and 
intravenously, without apparent cytotoxicity effects to normal cells (Geschwind, Ko et al. 2002; 
Ko, Smith et al. 2004). Moreover, recently was reported a first human translational study that 
demonstrate 3-BP efficacy and specificity in eradication of tumor, being in preclinical trials 
(Pelicano, Martin et al. 2006; Tennant, Duran et al. 2010; Ko, Verhoeven et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of metabolic targeting tumor strategies (Tennant, Duran et 
al. 2010). 5-FU – 5-fluorouracil; αKG – α-ketoglutarate; ACLY – ATP citrate lyase; CA – carbonic anhydrase; CINN 
– α-cyano-4-hydroxycinnamate; DCA – dichloroacetate; FASN – fatty acid synthase; G6P – glucose-6-phosphate; 
Glut – glucose transporter; HK – hexokinase; IGF1 – insulin-like growth receptor 1; IGF1R – IGF1 receptor; LDH –
lactate dehydrogenase; Mal – malate; MCT – monocarboxylate transporter; NHE1 – Na+/H+ exchanger 1; OAA – 
oxaloacetate; PDH – pyruvate dehydrogenase; PDK – pyruvate dehydrogenase kinase; PEP – phosphoenol pyruvate; 
PK – pyruvate kinase; R5P – ribose 5-phosphate; TCA – tricarboxylic acid cycle  
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1.4.1. 3-Bromopyruvate as an anticancer agent 
 
3-bromopyruvate (3-BP) is a pyruvate analog with anticancer activity (Ko, Pedersen et al. 
2001; Pedersen 2012; Shoshan 2012). This molecule is an alkylating agent able to inhibit the 
enzymatic function of several proteins by its pyruvylation at a -SH group of cysteine residue (Ko, 
Verhoeven et al. 2012). 3-BP suppresses both glycolysis and oxidative phosphorylation capacity 
decreasing the production of intracellular ATP and subsequently cause cell death (Ko, Pedersen 
et al. 2001). 
The most relevant targets of 3-BP to tumor metabolism are the glycolytic enzyme HK II, 
responsible for the phosphorylation of glucose to glucose-6-phosphate, and the mitochondrial 
ATP synthasome located in the inner mitochondrial membrane responsible for the generation of 
ATP (Ko, Pedersen et al. 2001; Ko, Smith et al. 2004; Chen, Zhang et al. 2009; Mathupala, Ko 
et al. 2009) (Figure 8). 3-BP covalently modify modifies the HKII, leading to its dissociation from 
the mitochondria and the release of apoptosis-inducing factor (AIF) and cell death (Chen, Zhang 
et al. 2009). 
Several studies have shown that 3-BP also inhibits others glycolytic enzymes such as 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Ganapathy-Kanniappan, Geschwind et al. 
2009; Ganapathy-Kanniappan, Vali et al. 2010), 3-phosphoglycerate kinase (PGK) (Pereira da 
Silva, El-Bacha et al. 2009), pyruvate kinase (PK) (Acan and Ozer 2001) and non-glycolytic 
enzymes such as vacuolar-type H+-ATPase (V-ATPase) (Dell'Antone 2006), 4-aminobutyrate 
aminotransferase (Blessinger and Tunnicliff 1992), sarco/endoplasmic reticulum calcium Ca2+- 
ATPase (SERCA) type 1 (Jardim-Messeder, Camacho-Pereira et al. 2012), histone deacetylases 
(HDAC1 and HDAC3) (Thangaraju, Karunakaran et al. 2009) and mitochondrial succinate 
dehydrogenase (Pereira da Silva, El-Bacha et al. 2009). Therefore, the effect of 3-BP include 
alteration in mitochondria dynamic by mitochondrial depolarization, decrease in cellular ATP 
levels from glycolysis and mitochondrial respiration (Pedersen 2007; Ihrlund, Hernlund et al. 
2008), induction of apoptosis pathway by release of apoptosis-inducing factor (AIF) (Kim, Ahn et 
al. 2008) and induction of endoplasmatic reticulum stress which inhibits protein synthesis 
(Ganapathy-Kanniappan, Geschwind et al. 2010) that lead to cell death. Although 3-BP targets 
have been identified, the precise mechanism of its uptake into cancer cells is poorly understood. 
Transport studies in Xenopus laevis oocytes expressed human SLC5A8 (SMCT1) and ectopic 
expression of SMCT1 in human breast cancer cell line MCF7 demonstrated that SMCT1 is 
involved in the transport of 3-BP into cells (Thangaraju, Karunakaran et al. 2009). Moreover, a 
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recent haploid cell genetic screening study performed in human leukemia cell line KBM7 showed 
that MCT1 is also involved in the transport of 3-BP (Birsoy, Wang et al. 2013). 
 Some studies demonstrated that 3-BP eradicate several types of tumors of advanced 
cancers. 3-BP anticancer effect was reported in human breast cancer by our group and others 
(Buijs, Vossen et al. 2009; Queiros, Preto et al. 2012), in rabbit VX2 model of hepatocarcinomas 
(Ko, Smith et al. 2004), in rabbit liver cancer (Ko, Pedersen et al. 2001; Geschwind, Ko et al. 
2002; Vossen, Buijs et al. 2008), in lung cancer (Zhang, Pan et al. 2012) and in mesothelioma 
(Philippe, Xiao-Dong et al. 2012). Moreover, 3-BP in combination with chemotherapeutic drugs 
induced a dose-dependent effect. 3-BP has a significant combinatory effect with cisplatin and 
oxaliplatin in HCT116 colon carcinoma cell line (Ihrlund, Hernlund et al. 2008). Combination with 
rapamycin show highly synergistic effect in both killing leukemia and lymphoma cells (Xu, 
Pelicano et al. 2005). The action of these two agents promotes the depletion of cellular ATP, and 
caused dephosphorylation of the mTOR downstream target molecules. In C6 glioma cells, the 
combination of 3-BP with citrate (inhibitor of phosphofructokinase) deplete ATP and block 
migratory capacity (El Sayed, El-Magd et al. 2012). More recently, it was also reported a first 
human patient case with fibrolamellar hepatocellular carcinoma known to treated with 3-BP, that 
demonstrate the eradication of tumor without apparent cytotoxicity to normal cells (Ko, 
Verhoeven et al. 2012). Several in vitro and in vivo studies with 3-BP demonstrates its potential 
clinical use as an anticancer agent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Main targets of 3-bromopyruvate molecule in cancer cells: (1) hexokinase II and (2) 
ATP synthasome (Mathupala, Ko et al. 2009). 
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1.5. Butyrate anti-carcinogenic potential in cancer cells 
 
Short-chain fatty acids (SCFAs), proprionate, acetate and butyrate are produced by colonic 
bacterial fermentation of dietary fiber in the intestinal lumen (Hamer, Jonkers et al. 2008). The 
production of butyrate is important for the maintenance of colonic homeostasis by inducing cell 
maturation, differentiation and apoptosis pathways (Gupta, Martin et al. 2006). Butyrate is a 
major primary energy source for colonocytes (Fleming, Fitch et al. 1991). At high levels (2-5 mM) 
function as a inhibitor of histone deacetylases (HDAC) resulting in hyperacetylation of histones 
and consequent decrease in their affinity for binding DNA and hence increases the accessibility 
for transcription genes silenced at epigenetic level (Donohoe, Collins et al. 2012). At low doses 
(0.5-1 mM) butyrate is metabolized in the mitochondria to acetyl-CoA by β-oxidation followed by 
TCA cycle to yield citrate. Citrate is exported to the cytosol and converted to acetyl-CoA by the 
enzyme ATP citrate lyase (ACL). In the nucleus, acetyl-CoA is a cofactor and acetyl-group donor 
for histone acetyltransferases (HATs) that promotes acetylation of histones (Figure 9) (Donohoe, 
Collins et al. 2012).  
As all weak carboxylic acids, SCFAs are partially ionized in solution. SCFAs have a pKa 
value approximately of 4.8, and more than 90% exist in the anionic form (dissociated form), 
ionized in physiologic conditions in the lumen (Hamer, Jonkers et al. 2008). Butyrate can be 
transported across the colonocyte apical membrane by simple diffusion of the undissociated form 
that is lipid soluble (Velazquez, Lederer et al. 1997), bicarbonate exchanger SCFA/HCO3- 
(Kawamata, Hayashi et al. 2007) and also by active transport of dissociated form by MCT1 (Cuff, 
Dyer et al. 2005) and SMCT1 (Gupta, Martin et al. 2006; Thangaraju, Cresci et al. 2008) 
The role of butyrate in intestinal lumen has been associated to anti-inflammatory and anti-
tumor activity (Inan, Rasoulpour et al. 2000; Hamer, Jonkers et al. 2008). In normal colonocytes 
low doses of butyrate (0.5-1 mM) promotes cell proliferation by HAT activity, in contrast to its 
effects on cancerous colonocytes. This opposite effect has been referred as “Butyrate paradox” 
and is poorly understood. The fact that butyrate at high levels can act as an HDAC inhibitor has 
been recently linked to this inhibitory growth effect in cancerous colonocytes (Donohoe, Collins et 
al. 2012). The upregulation of glycolysis in cancerous colonocytes due to the Warburg effect, 
results in accumulation of butyrate non metabolized in the nucleus where function as HDAC 
inhibitor to regulate genes that inhibited cell proliferation and promoted apoptosis (Donohoe, 
Collins et al. 2012). 
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Recently, our group demonstrated that pre-incubation with butyrate enhanced significantly 
3-BP cytotoxicity effect, especially in the most resistant human breast cancer cell line, SK-BR-3. 
Butyrate induced localization of MCT1 in the plasma membrane, as well as overexpression of 
MCT4 and its chaperon CD147 which were accompanied by an increased sensitivity to 3-BP 
cytotoxic effect (Queiros, Preto et al. 2012). 
 
 
Figure 9. Schematic overview of butyrate dual function in energetics and epigenetics in normal 
and cancerous colonocytes in the intestinal lumen. Butyrate is a primary energy source for normal 
colonocyte and is metabolized by β-oxidation to acetyl-CoA which is a cofactor for histone 
acetyltransferases (HATs) that regulate gene expression in the nucleus. In cancerous colonocyte that 
exhibit Warburg effect, butyrate accumulates in the nucleus where function as histone deacetylases 
inhibitor (HDACs) regulating  (Donohoe, Curry et al. 2013). 
 
 
1.6. Breast cancer 
 
Breast cancer is the most diagnosed malignancies and the leading cause of death related 
to cancer in women (Jemal, Bray et al. 2011). The incidence and mortality of this disease is 
growing and in 2008, were diagnosed 23% new cases of breast cancer and 14% of deaths related 
to cancer worldwide (Jemal, Bray et al. 2011). There are several factors that contribute to the 
risk of development breast cancer, such as environmental, hormonal, lifestyle, and genetic 
factors. The lifestyle related factors include late age of first pregnancy, oral contraceptive, 
hormone therapy after menopause, obesity and alcohol (Jemal, Center et al. 2010). Breast 
cancer family history is also an important risk factor, being BRCA1 and BRCA2 genes (breast 
cancer genes 1 and 2) the most predominant genetic mutations in hereditary breast cancer 
(King, Marks et al. 2003). 
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Breast cancer displays a variety of phenotypes at histological and molecular levels. The 
development of human breast cancer can start in epithelial cells of the mammary tissue, usually 
in the ductal luminal cells or in the terminal ductal lobular units (TDLUs) (Visvader 2009). 
According to the gene expression profiles, breast cancer can be cluster in five major molecular 
subtypes: luminal A (ER+ and/or PR+, HER-2-), luminal B (ER+ and/or PR+, HER-2+), HER2+ (ER-, 
PR-, HER-2+), basal-like (ER-, PR-, HER-2-) and normal-like (claudin-low) (Sorlie, Perou et al. 2001). 
The most important characteristic of these subtypes is the expression of progesterone receptor 
(PgR), estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER-2) (Sotiriou, 
Neo et al. 2003). The luminal subtype is characterized by the expression of ER; luminal A and B 
subtypes distinguish from each one by the absence or presence of HER-2 receptor, respectively. 
The molecular profile of HER-2 subtype shows the expression of HER-2 receptor. The basal-like 
subtype known as triple-negative breast cancer is distinguished by the absence of ER, PR and 
HER-2 receptors expression (Hudis and Gianni 2011). 
Treatment of breast cancer depends on the subtype of cancer and on its stage of 
evolution. Actually, there are several strategies that consists in local or systemic treatments (Al-
Ejeh, Smart et al. 2011). Local treatments include surgery and radiotherapy, and systemic 
treatments comprise chemotherapy, hormonal therapy or target therapy. Multidrug resistance 
and limitations in breast cancer chemotherapy emphasizes the need for new drugs to increase 
treatment efficacy (Li, Lewis et al. 2008). The mechanistic understanding of the molecular and 
biochemical events that occur in cancer cells is the starting point for the development of new 
treatments for breast cancer. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Rationale and Aims
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Rationale 
 
3-Bromopyruvate (3-BP) is an alkylating agent that acts in glycolytic metabolism inhibiting 
the activity of enzymes, such as hexokinase II which is overexpressed in cancer cells (Ko, 
Pedersen et al. 2001). This molecule has been further explored due to it potential as anticancer 
agent in the eradication of tumors in vitro and in vivo without cytotoxicity to normal cells (Ko, 
Pedersen et al. 2001; Ko, Smith et al. 2004). Monocarboxylate transporters (MCTs) are 
responsible for the transport of endogenous monocarboxylic acids such as pyruvate, lactate and 
butyrate (Halestrap and Wilson 2012) and exogenous monocarboxylates as 3-BP (Birsoy, Wang et 
al. 2013) across the plasma membrane. Little was known about the role of butyrate in the effect 
of 3-BP in cancer cells. Previous observations in our laboratory showed that pre-incubation with 
butyrate sensitized cells to 3-BP cytotoxic effect in the most resistant human breast cancer cell 
line, SK-BR-3 (Queiros, Preto et al. 2012). These observations also indicated that butyrate 
promoted the localization of MCT1 at the plasma membrane and enhanced the expression of 
MCT4 and its chaperon CD147 (Queiros, Preto et al. 2012). Knowing that butyrate can alter the 
expression of MCTs, the hypothesis that butyrate could regulate the cytotoxic effect of 3-BP was 
explored in this work.  
 
Aims 
 
This work aimed to characterize the effect of butyrate without or with 3-BP in four human 
breast cancer cell lines with different sensibilities to 3-BP (ZR-75-1> MCF-7> MDA-MB-231> 
SK-BR-3), and evaluate the expression of MCTs in these conditions. Our specific aims were the: 
 
1. Characterization of basal expression profile of MCTs and ancillary proteins important for 
their function, through western blot assay; 
2. Evaluation of cytotoxic effect of butyrate without or with 3-BP, by trypan blue exclusion 
assay; 
3. Evaluation of MCTs expression upon treatments, through western blot assay; 
4. Optimization of MCT1 and MCT4 silencing by RNA interference (RNAi) to further study 
its role in 3-BP effect; 
5. Evaluation the effect of butyrate without or with 3-BP on cell cycle by flow cytometry. 
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3.1. Cell lines and culture conditions 
 
In this study human breast cancer cell lines ZR-75-1, MCF-7, MDA-MB-231 and SK-BR-3 
were used. ZR-75-1 cell line is derived from ductal adenocarcinoma of mammary gland, subtype 
luminal A and is estrogen receptor positive (ER+). MCF-7 is derived from mammary gland 
adenocarcinoma, subtype luminal A, ER+. MDA-MB-231 is derived from adenocarcinoma of 
mammary gland, subtype basal and is ER-. SK-BR-3 is derived from mammary gland 
adenocarcinoma, subtype HER2+ and is ER-. All cell lines were obtained from American Type 
Culture Collection (ATCC, EUA). 
Cells were cultured in RPMI-1640 medium (PAA) supplemented with 10% heat inactivated 
fetal bovine serum (FBS) (Gibco, Life Technologies) and 1% antibiotic solution (penicillin-
streptomycin solution) (Gibco, Life Technologies), incubated at 37oC under a humidified 
atmosphere with 5% CO2, in an incubator. For the cell line MCF-7 the growth medium was also 
supplemented with 25 µg/ml insulin (Sigma). The maintenance of cell culture in 25 cm2 
polystyrene culture flasks (T25 flasks) (TPP), in exponential growth phase, was achieved by 
subculture when 80% confluence was reached, by treatment with 0.05% trypsin/EDTA solution 
(Sigma). 
 
 
3.2.  Preparation of carboxylic acid solutions 
 
Butyric acid and 3-bromopyruvate (3-BP) were purchased from Sigma and their solutions 
prepared in phosphate-buffered saline (PBS) at the concentrations of 200 mM and 12 mM, 
respectively, and further diluted in PBS to the desired final concentrations. Butyric acid solutions 
were adjusted to pH 7.4 and stored at 4oC in the maximum period of one week, and 3-BP 
solutions were prepared freshly at the days of treatment. All the solutions were sterilized by 
filtration (0.22 μm syringe filter units) before use and their addition to the culture medium never 
exceeded 10% of the final volume. 
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3.3.  Treatment conditions 
 
For treatment with butyric acid and 3-BP, cells in exponential growth phase were cultured 
in 6-well plates at a cellular density defined for each cell line and incubated at 37oC in a 5% CO2 
atmosphere during 24 hours, to allow cell adhesion. ZR-75-1, MCF-7 and SK-BR-3 were plated at 
a density of 250 000 cells per well and MDA-MB-231 was plated at 200 000 cells per well (final 
volume 1.5 ml/well). After 24 hours, culture medium was removed and replaced by fresh media 
containing different concentrations of butyric acid (0.5 mM and 10 mM) alone or in combination 
with the 3-BP in a concentration corresponding to the respective IC50 (half maximal inhibitory 
concentration) for each cell line (Table II). After treatment, cells were incubated for a further 16 
hours at 37oC, 5% CO2. For the negative controls fresh medium without butyric acid or 3-BP was 
added.  
 
Table II. IC50 values of 3-bromopyruvate for the breast cancer cell lines ZR-75-1, MCF-7, MDA-MB-
231 and SK-BR-3 used in this study (Queiros, Preto et al. 2012; Pacheco 2012). 3-BP – 3-bromopyruvate 
Cell line 3-BP IC50 (μM) 
ZR-75-1 55.7 ± 1.5 
MCF-7 84.6 ± 15.4 
MDA-MB-231 148.6 ± 28.1 
SK-BR-3 458.1 ± 28.6 
 
 
3.4. Trypan Blue exclusion assay 
 
Trypan Blue exclusion assay is a quick and reproductive method to evaluate cell viability. 
This is an impermeable dye that cannot penetrate the membrane of viable cells but can 
permeate non-viable cells, due to their compromised membrane resulting in a blue coloration. 
  
After applying the treatments described above, adherent cells were gently washed with 
PBS and trypsinized with 0.05% trypsin/EDTA at 37oC. The culture medium and the cell 
suspension were collected together in a centrifuge tube and then a sample of this suspension 
was mixed with 0.4% trypan blue solution (1:2, cell suspension:trypan blue). After a 5 minutes 
incubation at room temperature, viable cells (clear cells) and non-viable cells (blue staining cells) 
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were counted in a hemacytometer under a bright-field microscope. The viability was determined 
by dividing the number of viable cells by the total number of cells, and expressed as a 
percentage. 
 
 
3.5. Protein extraction and Western Blot analysis 
 
 
 3.5.1. Total protein extraction 
 
For the expression analysis of proteins at basal condition, cells were plated in 6-well plates 
(final volume 1.5 ml/well) at a density of 500 000 cells for ZR-75-1 and SK-BR-3, 350 000 cells 
for MCF--7 and 300 000 cells for MDA-MB-231 per well, for 24 hours. For the expression analysis 
of proteins after carboxylic acids treatment, ZR-75-1, MCF-7 and SK-BR-3 were plated at a density 
of 250 000 cells per well and MDA-MB-231 was plated at 200 000 cells per well in a 6-well 
plates (final volume 1.5 ml/well) for 24 hours. Cells were treated with different concentrations of 
butyric acid (0.5 mM and 10 mM) alone or in combination with respective 3-BP IC50 for each cell 
line, for 16 hours. After appropriate treatment, culture medium containing floating cells was 
recovered to a centrifuge tube and maintained on ice. Adherent cells were washed with PBS, 
trypsinized and collected to the same centrifuge tube. Cells were centrifuged at 2000 rpm for 10 
minutes at 4oC and pellets (500 μl) were transferred to eppendorfs tubes and 500 μl PBS were 
added. Pellets were centrifuged at 2000 rpm for 5 minutes at 4oC and supernatant was 
discarded. Then, 30 μl of ice-cold lysis buffer (150 mM NaCl, 0.1 mM EDTA, 1% Triton X-100, 1% 
NP40, 50 mM Tris-HCl pH 7.5) supplemented with 1/7 protease inhibitor cocktail (Roche 
Applied Sciences), was added to each sample and resuspended. Samples were incubated on ice 
during 10 minutes, occasionally vortexed. Cell lysates were centrifuged at 13 000 rpm for 15 
minutes at 4oC. Supernatants were collected to a new eppendorf tube and stored at -80oC until 
western blot assay. 
 
 
3.5.2. Protein Quantification 
 
Protein concentration was determined by BCA Protein Assay kit (Thermo scientific) which 
is a colorimetric assay based on Cu+2 reduction to Cu+1 by protein in an alkaline medium (biuret 
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reaction). The purple-colored reaction product exhibits a high absorbance at 562 nm directly 
proportional to protein concentration. 
 
Diluted bovine serum albumin (BSA) standards and working reagent (50:1, Reagent A:B) 
were prepared according to the standard protocol. In a 96-well plate 200 µl of working reagent 
were added to 10 µl of BSA standards or samples of total protein extracts diluted 1:20 in proper 
buffer. After incubation at 37oC for 30 minutes, absorbance was measure at 562 nm in a 
microplate reader (Spectra Max 340-PC, Molecular Devices). The protein concentrations of total 
protein extracts were obtained using the standard curve with the absorbance of BSA standards 
versus its concentration in µg/ml, and considering the dilution factor of the sample. 
 
 
3.5.3. Western Blot assay 
 
After total protein extraction and protein quantification described above, samples were 
processed to Western Blot assay. For that purpose, 25 μg of total protein samples were mixed 
with 5 μl of Laemmli Sample Buffer (final volume 25 μl) and denatured at 95oC for 5 minutes, 
followed by a shot spin. After protein denaturation, samples were separated electrophoretically on 
10% polyacrylamide gel (resolving gel solution: 375 mM Tris-HCl pH 8.8 SDS 0.4%, 15% glycerol, 
0.1% TEMED, 0.05% APS; stacking gel solution: 125 mM Tris-HCl pH 6.8 SDS 0.4%, 0.1% 
TEMED, 0.05% APS). Molecular weight marker (Precision Plus ProteinTM Dual Xtra Standards, 
BioRad) was used in all the blots to access protein size. The electrophoresis was performed in a 
Mini Protean Tetra System (Bio-Rad) electrophoresis system at 10 mA for 2 hours, using running 
buffer (0.025 M Tris base, 0.192 M Glycine, 0.1% SDS).  
The proteins separated in the polyacrylamide gel were then transferred to a polyvinylidene 
difluoride (PVDF) membrane (Millipore) previously hydrated with methanol. Electrotransfer 
occurred in a Mini Protean Tetra System (BioRad) at 54 mA for 1 hour, using transfer buffer 
(0.025 M Tris base, 0.192 M Glycine, 0.1% SDS, 20% methanol). Membranes were rinsing with 
PBS and blocked in PBS-T (PBS with 0.1% Tween-20) containing 5% non-fat dry milk (Molico) for 
1 hour at room temperature or overnight at 4oC, to block non-specific biding sites. Then, 
membranes were washed with PBS-T and incubated with the specific primary antibodies diluted 
in PBS-T with 5% non-fat dry milk or 5% BSA, overnight at 4oC, with agitation in a Roller Mix. After 
overnight, membranes were washed three times for 5 minutes with PBS-T to remove excess of 
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unbound antibody followed by incubation with appropriate secondary antibodies conjugated with 
IgG horseradish peroxidase diluted in PBS-T during 1 hour at room tempetature, with agitation in 
a Roller Mix. Membranes were washed three times with PBS-T for 15 minutes and protein 
immunodetection was revealed by chemiluminescence detection kit (Millipore), using the Chemi 
Doc XRS (BioRad). The intensity of bands was quantified using the ImageJ software and β-actin 
was used as internal control. The results of tree independent experiments were quantified and 
correspondent values were divided by the β-actin value. In order to reprobe with other antibodies, 
membranes were stripped with stripping glycine buffer (7.5 g Glycine, 0.5 g SDS, 5 ml Tween-20, 
pH 2.2) for two times during 10 minutes at room temperature following by two times washes for 
10 minutes with PBS-T. All primary antibodies and secondary antibodies and their dilutions used 
in this study are listed in Table III.  
 
Table III. List of primary and secondary antibodies conditions used in this study. FG – fully 
glycosylated; CG – core glycosylated. 
Protein Size (kDa) 
Primary antibody 
(company (reference); dilution) 
Secondary antibody 
(Jackson laboratories; 
dilution 1:5000) 
MCT1 43  Santa Cruz (sc-365501); 1:500 (5% milk) Anti-mouse  
MCT2 35  Santa Cruz (sc-14926); 1:500 (5% milk) Anti-mouse  
MCT4 43 Santa Cruz (sc-50329); 1:500 (5% BSA) Anti-rabbit  
AE1 (Band 3) 50 Abcam (ab-108414); 1:500 (5% milk) Anti-rabbit 
CD147 45-65 (FG) 
35 (CG) 
Santa Cruz (sc-71038); 1:100 (5% milk) Anti-mouse  
CD44 83 Serotec (MCA2726); 1:500 (5% milk) Anti-mouse  
β-actin 30 Santa Cruz (sc-47778); 1:2000 (5% BSA) Anti-mouse  
 
 
3.6. Cell cycle analysis 
 
Flow cytometry allows a quantitative characterization of multiple parameters of individual 
cells and their populations. Cell cycle analysis performed by flow cytometry allows a precise 
measurement of cellular DNA content and assessing the percentage of cells in the individual 
cell-cycle phases of interphase determined by peaks in a DNA content frequency histograms 
(Côrte-Real, Sansonetty et al 2002). 
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After appropriate treatments with carboxylic acids, medium containing floating cells and 
adherent cells trypsinized were collected to the same centrifuge tube, and centrifuged at 500 g 
for 3 minutes. The pellet was ressuspended in 500 μl and incubated on ice for 15 minutes. After 
this period, 1.5 ml of 100% cold ethanol (stored at -20oC) was added to pellet and incubated on 
ice during 15 minutes, to allow cell fixation. Cells were then washed with 3 ml PBS, centrifuged 
at 500 g for 3 minutes at 4oC and the pellet was washed with PBS. The final pellet was 
ressuspended in 500 μl PBS and incubated with 50 μl of RNase A solution (200 μg/ml in 
sodium citrate (1% w/v)) at 37oC for 15 minutes, to eliminate RNA. After 15 minutes incubation, 
50 μl propidium iodide (PI) staining solution (0.5 mg/ml in sodium citrate (1% w/v)) was added 
and after vortex cells were incubated at room temperature for 30 minutes in the dark. Cells with 
red fluorescence (FL-3 channel (488/620 nm)) were analyzed in Epics XL flow cytometer 
(Beckman Coulter) with an average of 20 000 counts per sample. Data were analyzed with the 
FlowJo software to generate DNA content frequency histograms and quantify the amount of cells 
in each phases of interfase, including sub-G1 population assumed as death cells (cells with less 
than normal amount of DNA content). 
 
 
3.7. Fluorescence microscopy: actin evaluation 
 
ZR-75-1 and SK-BR-3 cells were cultured in 24 well-plates at a cell density of 150 000 cells 
per well (final volume 500μl/well) and incubated at 37oC with 5% CO2 during 24 hours to adhere. 
Then, cells were treated with 3-BP in a concentration corresponding to the respective IC50 for 
each cell line, as described above, and in controls medium was refreshed. After 16 hours of 
proper incubation, medium with floating cells was discarded and adherent cells were washed 
with prewarmed PBS (pH 7.4) two times, and fixed with 3.7% formaldehyde solution in PBS for 
10 minutes at room temperature. After fixation, cells were washed twice with PBS. Then 
permeabilized with 0.1% Triton X-100 in PBS for 4 minutes, washed with PBS and incubated with 
Alexa Fluor 488 Phalloidin (Gibco, Life Technologies) fluorescent probe with high affinity to 
filamentous actin (F-actin) diluted 1:40 in PBS for 20 minutes at room temperature, protecting 
from light. For double staining, cells were subsequently incubated with Vectashield Mounting 
Medium with DAPI (Vector Laboratories) for 20 minutes, to stain nucleus. Cells were washed 
twice with PBS to remove the excess labeling and photographed using fluorescence microscope 
Olympus IX71. 
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3.8. Silencing of MCTs by RNA interference assay  
 
RNA interference (RNAi) is a mechanism for silencing gene expression by targeting a 
specific mRNA to degradation. Small interfering RNA (siRNA) is the main effector of the post-
transcriptional gene silencing. In the cell, the siRNA is recognized and incorporated by RNA-
induced silencing complex (RISC) that leads to the cleavage of sense strand of RNA by argonaute 
2 (AGO2). Subsequently, the active complex RISC-siRNA binds and degrades complementary 
mRNA resulting in the silencing of specific target gene (Agrawal, Dasaradhi et al. 2003). 
 
The inhibition of MCT1 and MCT4 expression in the different breast cancer cell lines was 
performed by RNAi. For the optimization of RNAi transfection conditions according to reverse 
transfection method a fluorescent control siRNA non-target labeled with Alexa Fluor 488 (all stars 
negative siRNA, AF-488, Qiagen) was used and the efficacy and cytotoxicity of transfection 
reagent Lipofectamine RNAiMAX (Invitrogen) in delivery exogenous siRNA to cells were assessed 
by fluorescence microscopy and trypan blue exclusion assay, respectively. 
 
 
3.8.1. Optimization of RNAi transfection conditions 
 
The optimization of siRNA transfection conditions in ZR-75-1, SK-BR-3 and MCF-7 cell lines 
were performed according to reverse transfection method (Gallagher, Castorino et al. 2007). 
For the transfection mix, 0.5, 1 and 2 µl of transfection reagent Lipofectamine RNAiMAX 
(Invitrogen) were diluted in Opti-MEM (Reduced serum medium) (Gibco) and incubated 5 minutes 
at room temperature. After incubation, 5 nM of fluorescent control siRNA non-target labeled with 
Alexa Fluor 488 (all stars negative siRNA, AF-488, Qiagen) were added to a transfection mix (final 
volume of 250 µl) and incubated more 15 minutes at room temperature. Controls were 
performed with Opti-MEM alone. Cells were plated in 6-well plates at a density of 100 000 cells 
for ZR-75-1 and MCF-7, and 50 000 cells for SK-BR-3 per well (final volume 1.5 ml/well). Cell 
suspension was prepared in RPMI supplemented with 10% heat inactivated FBS without 
penicillin/streptomycin antibiotic. Transfection mix and 750 µl of cell suspension previously 
prepared were distributed by each condition in 6-well plates with coverslips and incubated at 
37oC with 5% CO2 for 24 hours, to cells adhere. All transfections were performed with solutions 
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and materials RNAse free. After 24 hours, medium was refreshed with RPMI complete medium 
supplemented with 10% heat inactivated FBS and 1% penicillin/streptomycin.  
In the fourth day of silencing, the cellular uptake of fluorescent control siRNA non-target 
labeled with Alexa Fluor (siRNA-AF) was accessed by fluorescence microscopy and the 
cytotoxicity of transfection was determined by trypan blue exclusion assay. For the fluorescence 
microscopy, cells grown in coverslips were washed with PBS and fixed with 4% paraformaldehyde 
(PFA) during 30 minutes at room temperature. After fixation, coverslips were mounted in 
Vectashield Mounting Medium with DAPI (Vector Laboratories) to stain nucleus and photographed 
by Leica DM 500B fluorescence microscope in appropriate protocol in LAS AF software (Leica). 
Cells with green fluorescence in the cytoplasm were considered to contain internalization of 
siRNA-AF. Cytotoxic evaluation of the transfection reagent Lipofectamine RNAiMAX was 
performed by trypan blue exclusion assay as described above. The viability was determined by 
dividing the number of viable cells by the total number of cells and expressed as a percentage. 
 
 
3.8.2. MCT1 and MCT4 silencing by RNAi 
 
MCT1 and MCT4 expression was silenced with siRNA using transfection conditions 
optimized for reverse method. siRNAs were purchased from Ambion. ZR-75-1 and SK-BR-3 cells 
were transfected with siRNAs specific for MCT1 (SLC16A1 siRNA, catalog number 4390824) and 
MCT4 (SLC16A3 siRNA, catalog number 4390824) using Lipofectamine RNAiMAX (Invitrogen). 
The non-silencing siRNA control (catalog number 4390843) was used as negative control. siRNA 
transfection was performed using and 1 μl, 2 μl of Lipofectamine RNAiMAX for ZR-75-1 and SK-
BR-3, respectively, and 5 nM, 10 nM of siRNA. Knockdown of target genes were confirmed at the 
protein level by western blot analysis in the fourth and/or fifth day of silencing. 
 
 
3.9. Statistical analysis 
 
The results are represented as mean ± standard error of the mean (SEM) of at least three 
independent experiments. Statistical analyses were performed using GraphPad Prism Software 
v5.00 (California, USA). A p value < 0.05 was considered statistically significant. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Results 
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4.1. Basal expression profile of MCTs and ancillary proteins in breast cancer cell 
lines 
 
The expression of MCT1, MCT4, CD147, CD44 and AE1 was evaluated by western blot 
assay in ZR-75-1, MCF-7, MDA-MB-231 and SK-BR-3 human breast cancer cell lines using 
specific antibodies. Our results showed that the four breast cancer cell lines presented different 
expression profile for the analyzed proteins (Figure 10). 
 
Figure 10. Expression analysis of MCT1, MCT4, CD147, CD44 and AE1 in ZR-75-1, MCF-7, 
MDA-MB-231 and SK-BR-3 breast cancer cell lines at basal conditions. (A) Western blot of all proteins 
tested as indicated in the left part of the blots. Protein molecular weights observed are consistent to 
describe for these proteins and are showed at the right of the blots. β-actin level was used as loading 
control. A representative experiment of at least three independent experiments is shown. (B) 
Quantification of proteins levels. Bands were quantified in ImageJ software and values are expressed as 
mean ± standard error of the mean (SEM) of at least three independent experiments. FG – Fully 
glycosylated; CG – core glycosylated 
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MCT1 protein expression was detected in all cell lines, while MCT4 was highly expressed 
in ZR-75-1 and MDA-MB-231 and at low levels in MCF-7 and SK-BR-3. CD147, a ancillary protein, 
was expressed in all cell lines, although with different expression levels. The maturated form of 
CD147 fully glycosylated (FG) (45-65 KDa) and immature form core glycosylated (CG) (35-40 
KDa) were highly expressed in ZR-75-1 and at very lower levels in SK-BR-3. CD44, a ancillary 
protein, was expressed in all cell lines, however, MDA-MB-231 and SK-BR-3 expressed this 
protein at very low levels. AE1/Band 3, a pH regulator system, showed multiple bands being the 
band of 90 kDa the membrane protein that was only expressed in ZR-75-1 and MCF-7, 
presenting higher levels in ZR-75-1 cell line. 
 
 
4.2. Effect of butyrate and 3-BP treatment on cell viability 
   
The effect of butyrate, applied without or with 3-BP IC50, on cell viability of breast cancer 
cell lines was evaluated by the Trypan Blue exclusion assay. Cells were treated with two 
concentrations of butyrate (0.5 mM and 10 mM) alone or in combination with the respective 3-
BP IC50 for each cell line, for 16 hours. The Trypan Blue exclusion assay results showed different 
effects on cell viability in response to treatment with butyrate alone or butyrate in co-incubation 
with 3-BP IC50 (Figure 11). 
Butyrate decreased the percentage of viable cells dependent on its concentration in all cell 
lines. In ZR-75-1 and MCF-7, the cell lines more sensitive to 3-BP, treatment with 0.5 mM 
butyrate resulted in cell viability similar to negative control, being 101% for ZR-75-1 and 99% for 
MCF-7. Treatment with 10 mM butyrate decreased the percentage of viable cell to 63% in ZR-75 
cells and to 79% (p<0.05) in MCF-7 cells compared to the negative control. However, 
co-incubation of 0.5 mM butyrate with 3-BP IC50 resulted in cell viability similar to treatment with 
3-BP IC50 alone being approximately 45% in both ZR-75-1 and MCF-7 cell lines, while the co-
incubation of 10 mM butyrate with 3-BP IC50 resulted in increased percentage of viable cell being 
90% (p<0.05) and 87% (p<0.001) in ZR-75-1 and MCF-7, respectively compared to treatment 
with 3-BP IC50 alone. In MDA-MB-231 cells, treatment with 0.5 mM butyrate did not altered the 
percentage of viable cells being 99%, while treatment with 10 mM butyrate decreased cell 
viability to 71% (p<0.05) compared to negative control. Co-incubation of 0.5 mM butyrate with 
3-BP IC50 increased the percentage of viable cells being 78%, while co-incubation of 10 mM 
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butyrate with 3-BP IC50 has no effect on the percentage being 58%, compared to treatment with 
3-BP IC50 alone. In SK-BR-3 cell line, the cell line more resistant to 3-BP, treatment with 0.5 mM 
butyrate reduced the percentage of cell viability to 85% (p<0.05), while treatment with 10 mM 
butyrate decreased to 77% (p<0.001) compared to negative control. Co-incubation of 0.5 mM 
butyrate with 3-BP IC50 increased the percentage of cell viability to 90% (p<0.001) compared to 
treatment with 3-BP IC50 alone, while treatment of 10 mM butyrate with 3-BP IC50 increased the 
percentage of viable cells to 82% (p<0.05) compared to treatment with 3-BP IC50 alone. 
Observation of cells under the microscope showed cellular confluence at 16 hours after 
treatment with butyrate (0.5 and 10 mM) alone or in combination with 3-BP IC50 for each breast 
cancer cell line (Figure 12), confirming the results of Trypan Blue exclusion assay (Figure 11). 
Simultaneous treatment of 0.5 mM butyrate with 3-BP IC50 potentiated the effect of 3-BP in 
the cell lines more sensitive to 3-BP, ZR-75-1 and MCF-7, but not in the most resistant cell lines 
MDA-MB-231 and SK-BR-3.  
 
 
Figure 11. Effect of butyrate (0.5 mM and 10 mM) alone or in combination with 3-BP IC50 on cell 
viability of ZR-75-1, MCF-7, MDA-MB-231 and SK-BR-3 breast cancer cell lines, after 16 hours of 
incubation. At 16 hours after treatment, cells were collected, stained with trypan blue and counted. Cells 
were incubated with complete medium without acid treatment as a negative control. The number of viable 
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cells was expressed as a percentage relative to negative control. Results are mean ± standard error of the 
mean (SEM) of at least three independent experiments. Values significantly different from negative control: 
* p<0.05; ** p<0.01; *** p<0.001. Values significantly different from 3-BP IC50: # p<0.05; ### p<0.001, 
One-way ANOVA and Tukey Test. 
´ 
 
 
 
Figure 12. Analysis of cellular confluence of ZR-75-1, MCF-7, MDA-MB-231 and SK-BR-3 breast 
cancer cell lines at 16 hours, after treatment with butyrate (0.5 and 10 mM) alone or in combination with 
3-BP IC50. Negative control corresponds to cells submitted to the same conditions but without carboxylic 
acid treatment. Representative photos are shown. The scale bar corresponds to 500 μm. 
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4.3. Effect of butyrate and 3-BP treatment on MCTs expression 
 
In order to explore whether the viability phenotypes observed were associated to the 
capacity of butyrate to induce MCTs expression as already described by our group (Queiros, 
Preto et al. 2012), cells were treated under the conditions described above for 16 hours, and the 
expression of MCT1, MCT2, MCT4, CD147, CD44 proteins was accessed by western blot. 
For the most sensitive cell line, ZR-75-1, treatment with 3-BP IC50 increased MCT1, MCT2 
and MCT4 protein expression compared to the negative control (Figure 13). Western blot analysis 
showed that 0.5 mM and 10 mM butyrate decreased the expression of MCT4 but not MCT1, 
MCT2 and both forms of CD147 (FG and CG) compared to negative control. Co-incubation of 0.5 
mM butyrate with 3-BP IC50 increased the expression of MCT1, MCT2 and MCT4, while the 
combination of 10 mM butyrate with 3-BP IC50 decreased the expression levels of these proteins. 
Treatment with 3-BP IC50 alone and in co-incubation with 0.5 mM butyrate also decreased the 
levels of β-actin protein (Figure 13). 
 
Figure 13. Expression analysis of MCT1, MCT2, MCT4 and CD147 in ZR-75-1 breast cancer cell 
line after treatment with butyrate (0.5 mM and 10 mM) alone or in combination with 3-BP IC50 for 16 
hours. (A) Western blot of all proteins tested as indicated in the left part of the blots. Protein molecular 
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weights observed are consistent to describe for these proteins and are showed at the right of the blots. 
Cells were incubated with complete medium without acid treatment as a negative control. β-actin level 
was used as loading control. (B) Quantification of proteins levels relative to negative control. Bands were 
quantified in ImageJ software. FG – fully glycosylated; CG – core glycosylated 
 
 
In MCF-7 cell line, the β-actin expression was not detected in untreated cells (negative 
control), while treatment with 0.5 mM of butyrate increased the expression of MCT4 compared to 
10 mM of butyrate (Figure 14 (left panel)). Treatment with 3-BP IC50 alone or in combination with 
0.5 mM but not 10 mM of butyrate increased the MCT2 expression and decreased the 
expression levels of β-actin protein (Figure 14 (right panel)). MCT1 and CD147 were not 
detectable after stripping of the membranes. 
 
 
Figure 14. Expression analysis of MCT2, MCT4 and CD44 in MCF-7 breast cancer cell line after 
treatment with butyrate (0.5 mM and 10 mM) alone or in combination with 3-BP IC50 for 16 hours. 
Western blot of all proteins tested as indicated in the left part of the blots. Protein molecular weights 
observed are consistent to describe for these proteins and are showed at the right of the blots. Cells were 
incubated with complete medium without acid treatment as a negative control. β-actin level was used as 
loading control. * corresponds to the MCT2 protein band.  
 
 
In MDA-MB-231 cell line, treatment with 3-BP IC50 increased the expression of MCT4 but 
not MCT1 (Figure 15). Treatment with both concentrations of butyrate (0.5 mM and 10 mM) did 
not alter the expression of MCT1 and MCT4, while the combination with 3-BP IC50 increased 
MCT4 and decreased MCT1 expression (Figure 15). MCT2 expression was not detected in any 
tested conditions (Figure 15). CD147 was not detectable after stripping of the membrane. 
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Figure 15. Expression analysis of MCT1, MCT2 and MCT4 in MDA-MB-231 breast cancer cell line 
after treatment with butyrate (0.5 mM and 10 mM) alone or in combination with 3-BP IC50 for 16 hours. 
(A) Western blot of all proteins tested as indicated in the left part of the blots. Protein molecular weights 
observed are consistent to describe for these proteins and are showed at the right of the blots. Cells were 
incubated with complete medium without acid treatment as a negative control. β-actin level was used as 
loading control. (B) Quantification of proteins levels relative to negative control. Bands were quantified in 
ImageJ software.  
 
 
In the more resistant cells to 3-BP, SK-BR-3, MCT2 expression was not detected in any 
tested conditions (Figure 16). Treatment with 3-BP IC50 increased MCT1 and MCT4 expression, 
but decreased the expression of fully glycosylated (FG) form of CD147 compared to negative 
control. Both concentrations of butyrate (0.5 mM and 10 mM) alone or in combination with 3-BP 
IC50 increased the expression of MCT4, MCT1 and both forms of CD147 (Figure 16). 
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Figure 16. Expression analysis of MCT1, MCT2, MCT4 and CD147 in SK-BR-3 breast cancer cell 
line after treatment with butyrate (0.5 mM and 10 mM) alone or in combination with 3-BP IC50 
simultaneously for 16 hours. (A) Western blot of all proteins tested as indicated in the left part of the blots. 
Protein molecular weights observed are consistent to describe for these proteins and are showed at the 
right of the blots. Cells were incubated with complete medium without acid treatment as a negative 
control. β-actin level was used as loading control. (B) Quantification of proteins levels relative to negative 
control. Bands were quantified in ImageJ software. FG – fully glycosylated; CG – core glycosylated 
 
 
4.4. Effect of 3-BP on actin structure 
    
The results obtained by western blot in the expression levels of actin after 3-BP treatment 
led us to study the effect of 3-BP on actin structure in ZR-75-1 and SK-BR-3 cell lines. For that 
propose, cells were treated with 3-BP in a concentration corresponding to the respective IC50 for 
each cell line, for 16 hours. After 16 hours, cells were stained with Alexa Fluor 488 Phalloidin, a 
fluorescent probe specific for filamentous actin (F-actin) and visualized in a fluorescence 
microscope (Figure 17). Our preliminary results showed that treatment with 3-BP IC50 seems to 
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reduced the amount of actin in ZR-75-1 but not in SK-BR-3 cell line, what is in according to the 
results of western blot for actin protein (Figure 13 and 16). For ZR-75-1 cells, 3-BP treatment 
also altered the actin appearance and cellular shaping of cells from elongate to round cells, while 
in SK-BR-3 this phenotypic alteration was not so evident (Figure 17). 
 
 
 
Figure 17. Actin structural alterations in ZR-75-1 and SK-BR-3 cell lines, after treatment with 3-BP 
IC50 for 16 hours. Cells were incubated with complete medium without 3-BP treatment as a negative 
control. Alexa Fluor 488 Phalloidin stains for F-actin in red, and DAPI stains nucleus in blue. 
Representative photos of two independent experiments with similar results are shown. 
 
 
4.5. Optimization of MCT1 and MCT4 silencing by RNA interference 
 
In order to determine the contribution of monocarboxylate transporters (MCTs) on butyrate 
and 3-BP effect in breast cancer cells, the conditions for MCT1 and MCT4 silencing by RNA 
interference (RNAi) were optimized. For the optimization of the reverse transfection conditions, 
Lipofectamine RNAiMAX was used as a vehicle capable to delivery exogenous siRNA into cells. 
Firstly, the initial cellular density was optimized in ZR-75-1, MCF-7 and SK-BR-3 cells for the RNAi 
assay. The cellular density was determined in order to ensure 80% confluence in the fourth day of 
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transfection. Different cellular densities for each cell line were inoculated and cellular confluence 
was visualized by phase contrast microscope. In ZR-75-1 and MCF-7 cell lines were determined 
cell density of 100 000 cells and in SK-BR-3 cell line of 50 000 cells. To ensure the best 
conditions for siRNA delivery with high efficiency and low cytotoxicity different quantities of 
lipofectamine (0.5 μl, 1 μl and 2 μl) were tested in cellular viability/cytotoxicity and in 
internalization capability of a non-target siRNA labeled with Alexa Fluor 488 (siRNA-AF). After four 
days of transfection, the cytotoxicity of Lipofectamine RNAiMAX was evaluated by trypan blue 
exclusion assay and the cellular uptake of siRNA-AF was accessed by fluorescence microscopy 
(Figure 18). 
For ZR-75-1, trypan blue exclusion assay results showed that both 0.5 μl and 2 μl of 
Lipofectamine RNAiMAX did not altered cell viability (100%) and 1 μl of Lipofectamine RNAiMAX 
condition has no significant reduction on cellular viability compared to the negative control being 
92% (Figure 18A). Analysis of siRNA-AF cellular uptake in ZR-75-1 indicated that 1 μl of 
Lipofectamine RNAiMAX presented more internalization of siRNA-AF than the other conditions 
(Figure 18B). In MCF-7, the Lipofectamine RNAiMAX also seems to be non-cytotoxic for cells 
since the percentage of viability was 100% in 0.5 μl and 1μl of Lipofectamine RNAiMAX 
conditions and 94% for 2 μl of Lipofectamine RNAiMAX compared to negative control. 
Fluorescence microscopy allowed to determine that 1 μl of Lipofectamine RNAiMAX presented 
more siRNA-AF located in the cellular cytoplasm than the other conditions (Figure 18B). Finally, 
in SK-BR-3 the trypan blue exclusion assay demonstrated that Lipofectamine RNAiMAX was not 
cytotoxic in all tested conditions and 2 μl of Lipofectamine RNAiMAX demonstrated the better 
internalization of siRNA-AF (Figure 18). The results indicated that the combination of 1 μl of 
Lipofectamine RNAiMAX transfection reagent with 5 nM of siRNA presented the better condition 
for further silencing in ZR-75-1 and MCF-7 cell lines, and the combination 2 μl of Lipofectamine 
RNAiMAX with 5 nM in SK-BR-3 cell line.   
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Figure 18. Optimization of RNAi reverse transfection conditions with Lipofectamine RNAiMAX 
transfection reagent in ZR-75-1, MCF-7 and SK-BR-3 cell lines using non-target siRNA labeled with Alexa 
Fluor 488 (5 nM). (A) Cell lines were transfected with 0.5 μl, 1 μl and 2 μl of Lipofectamine RNAiMAX. 
After 4 days, cell viability was determined by trypan blue exclusion assay and expressed as a percentage. 
Negative control was performed with Opti-MEM alone. (B) Cellular internalization of non-target siRNA 
labeled with Alexa Fluor 488 (siRNA-AF) by transfections with different quantities of Lipofectamine 
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RNAiMAX (0.5, 1 and 2 μl). After 4 days, siRNA-AF fluorescence (green) and nuclei stain with DAPI (blue) 
was visualized by fluorescence microscopy. Representative photos are shown (20x magnification). 
 
 
For the optimization of MCT1 and MCT4 inhibition by RNAi we tested two different 
concentrations (5 nM and 10 nM) of siRNA target for MCT1 and MCT4 in ZR-75-1 and SK-BR-3 
cell lines. After four and/or five days of transfection knockdown of target genes was confirmed at 
protein level by western blot. 
In ZR-75-1 cell line, after four days of transfection with 5 nM of siRNA target MCT1 the 
expression of MCT1 protein decreased 2%, while with 10 nM of siRNA decreased 6%, compared 
to non-silencing siRNA control (siRNA control) (Figure 19). After five days of transfection with both 
5 nM and 10 nM of siRNA target MCT1 the expression of MCT1 protein increased 51% and 79%, 
respectively compared to siRNA control (Figure 19). 
 
 
 
Figure 19. Expression analysis of MCT1 protein after siRNA-mediated silencing with siRNA target 
MCT1 in ZR-75-1 breast cancer cell line in the fourth and fifth days of transfection. (A) Western blot of 
MCT1 as indicated in the left part of the blot. Protein molecular weight observed is consistent to describe 
for this protein and is showed at the right of the blot. β-actin level was used as loading control. Negative 
control was performed with Opti-MEM alone and siRNA control was performed with non-silencing siRNA. 
(B) Quantification of proteins levels relative to negative control in the fourth and fifth day of silencing. 
Bands were quantified in ImageJ software. 
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The western blot analysis of silencing with siRNA target MCT4 in ZR-75-1 cell line showed 
that in the fourth day of transfection 5 nM of siRNA MCT4 increased 16% of MCT4 protein 
expression, while 10 nM of siRNA MCT4 decreased 12% of MCT4 expression, compared to non-
silencing siRNA control (siRNA control) (Figure 20). After five days of transfection with both 5 nM 
and 10 nM of siRNA MCT4 reduced 20% of MCT4 protein expression, compared to siRNA control 
(Figure 20). 
 
 
Figure 20. Expression analysis of MCT4 protein after siRNA-mediated silencing with siRNA target 
MCT4 in ZR-75-1 breast cancer cell line in the fourth and fifth days of transfection. (A) Western blot of 
MCT4 as indicated in the left part of the blot. Protein molecular weight observed is consistent to describe 
for this protein and is showed at the right of the blot. β-actin level was used as loading control. Negative 
control was performed with Opti-MEM alone and siRNA control was performed with non-silencing siRNA. 
(B) Quantification of proteins levels relative to negative control in the fourth and fifth day of silencing. 
Bands were quantified in ImageJ software. 
 
 
In the SK-BR-3 cell line, western blot analysis of silencing with siRNA target MCT1 showed 
that, transfection with 5 nM of siRNA MCT1 decreased 17.7% of MCT1 protein expression, while 
10 nM of siRNA MCT1 decreased 28.8% of MCT1 expression compared to the non-silencing 
siRNA control, after five days of transfection (Figure 21). The transfection with non-silencing 
siRNA control (siRNA control) decreased 60% of MCT1 protein expression compared to the 
negative control. 
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Figure 21. Expression analysis of MCT1 protein after siRNA-mediated silencing with siRNA target 
MCT1 in SK-BR-3 breast cancer cell line in the fifth day of transfection. (A) Western blot of MCT1 as 
indicated in the left part of the blot. Protein molecular weight observed is consistent to describe for this 
protein and is showed at the right of the blot. β-actin level was used as loading control. Negative control 
was performed with Opti-MEM alone and siRNA control was performed with non-silencing siRNA. (B) 
Quantification of proteins levels relative to negative control in the fifth day of silencing. Bands were 
quantified in ImageJ software. 
 
 
 
The western blot analysis of silencing with siRNA target MCT4 in SK-BR-3 cell line revealed 
that transfection with 5 nM of siRNA MCT4 decreased 71% of MCT4 protein expression, while 10 
nM of siRNA MCT4 decreased 66% of MCT4 expression compared to non-silencing siRNA control 
(Figure 22). We also evaluated whether the down-regulation of MCT4 in these conditions led to 
alterations in expression levels of MCT1 and ancillary proteins CD44/CD147 (Figure 22). 
Western blot analysis of MCT4 silencing showed that 10 nM of siRNA MCT4 decreased 46% of 
MCT1 and 50% of CD44 expression compared to the non-silencing siRNA control. Treatment with 
5 nM of siRNA MCT4 decreased 17% of fully glycosylate (FG) form of CD147, while treatment 
with 10 nM of siRNA MCT4 decreased 96%, compared to non-silencing siRNA control. 
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Figure 22. Expression analysis of MCT1, MCT4 and CD147 after siRNA-mediated silencing with 
siRNA target MCT4 in SK-BR-3 breast cancer cell line in the fifth day of transfection. (A) Western blot of 
MCT1, MCT4 and CD147 as indicated in the left part of the blot. Protein molecular weights observed are 
consistent to describe for these protein and are showed at the right of the blot. β-actin level was used as 
loading control. Negative control was performed with Opti-MEM alone and siRNA control was performed 
with nonsilencing siRNA. (B) Quantification of proteins levels relative to negative control in the fifth day of 
silencing. Bands were quantified in ImageJ software.  
 
 
4.6. Effect of butyrate and 3-BP treatment on the cell cycle 
 
To evaluate the effect of butyrate alone or in combination with 3-BP on the cell cycle, 
exponentially growing cells were treated as described above for 16 hours and the cell cycle 
distribution was determined by flow cytometry using propidium iodide (PI) as a probe for DNA. 
Cell cycle analysis showed that, after 16 hours, ZR-75-1, MCF-7 and SK-BR-3 cell lines 
exhibited a higher percentage of cells with sub-G1 DNA content in negative control, indicative of 
higher cell death. Moreover, cells with G2 and S DNA content were not possible to identify in the 
histograms of these cell lines (data not showed).  
In MDA-MB-231 cells, treatment with 3-BP IC50 alone did not altered the percentage of cells 
with G1 DNA content (31%), S DNA content (44%) and G2 DNA content (26%) compared to 
negative control (Figure 23A and 23B). Lower concentration of butyrate (0.5 mM) alone or in 
combination with 3-BP IC50 did not altered the percentage of cells with G1 DNA content relative to 
negative control being approximately 31%, while only the co-incubation of 0.5 mM butyrate with 
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3-BP IC50 decreased the percentage of cells with G2 DNA content from 22% to 8%, compared to 
negative control. Treatment with 10 mM of butyrate alone or in combination with 3-BP IC50 
increased the percentage of cells with G1 DNA content to 52% and 51%, respectively, compared 
to negative control (32%) (Figure 23A and 23B). Moreover, treatment with 10 mM of butyrate 
alone or in combination with 3-BP IC50 decreased the percentage of cells with S phase DNA 
content from 46% (negative control) to approximately 40%, while the percentage of cells with G2 
DNA decreased from 22% (negative control) to 9% and 11%, respectively (Figure 23A and 23B). 
Treatment with 3-BP IC50 alone, increased the percentage of cells with less than normal amount 
of DNA content (sub-G1 DNA content) from 2% to 4%, compared to negative control (Figure 23C). 
Lower concentration of butyrate (0.5 mM) alone or in combination with 3-BP IC50 did not altered 
the percentage of cells with sub-G1 DNA content being 2% and 3% respectively, compared to 
negative control. Higher concentration of butyrate (10 mM) alone or in combination with 3-BP IC50 
increased the sub-G1 population to 5% and 4%, respectively compared to negative control (Figure 
23C).  
 
 
Figure 23. Analysis of the effect of butyrate (0.5 and 10 mM) alone or in combination with 3-BP 
IC50 on cell cycle of MDA-MB-231 breast cancer cell line, after 16 hours by flow cytometry. (A) 
Representative monoparametric histograms of DNA (number of cells versus relative DNA content) of 
indicated cell lines after staining with propidium iodide (PI). Cells were incubated with complete medium 
without acid treatment as a negative control. (B) Percentage of cells distribution of cell-cycle phases (G1, 
S, G2). (C) Percentage of cells with sub-G1 DNA content (cells with less than normal amount of DNA 
content).
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Reprogramming of cellular energy metabolism is an emerging hallmark of invasive 
carcinoma (Hanahan and Weinberg 2011). Carcinogenesis process has been associated with 
upregulation of metabolic pathways, mainly glycolysis. Cancer cells that exhibit Warburg effect 
depend on glycolysis for the production of ATP even in aerobic conditions. The export of 
accumulated lactate across the plasma membrane is mediated by MCTs upregulated in cancer 
cells, thereby protecting themselves from intracellular acidification. Given the importance of 
glycolysis in the tumor context, metabolic anticancer strategies are being explored. 3-BP is an 
alkylating agent able to inhibit metabolic pathways, namely glycolysis and oxidative 
phosphorylation, decreasing the production of ATP and causing cell death specifically in cancer 
cells (Ko, Pedersen et al. 2001). Breast cancer is the most common and lethal tumor in women 
worldwide, in which ER (-) breast cancers are known to be more aggressive, highly hormonal 
therapy resistance and associate with worse prognosis (Jemal, Bray et al. 2011). Thus, the 
identification of new therapeutic strategies is crucial. In the present work, the effect of butyrate 
alone or in combination with 3-BP in four human breast cancer cell lines were evaluated.  
 
 
5.1. MCTs basal expression profile 
 
In the present work, the expression profile of proteins involved in the transport of 
monocarboxylic acids was assessed by western blot, in four human breast cancer cell lines. All 
cell lines showed different basal expression profile of MCTs and ancillary proteins essential to 
their function. MCT1 expression was detected in two luminal subtype cell lines (ZR-75-1 (ER+) 
and MCF-7 (ER+)) and in subtype HER2+ (SK-BR-3 (ER-)) as described by Queirós and colleagues 
in immunohistochemistry studies (Queiros, Preto et al. 2012). The basal-like subtype 
MDA-MB-231 (ER-) also showed expression of MCT1, our results are not according to what has 
been previously reported showing that MCT1 is not expressed in this cell line, since alteration in 
the gene promoter results in loss of protein expression (Asada, Miyamoto et al. 2003; Hussien 
and Brooks 2011). In this study the evaluation of MCT2 expression was not performed since it 
was not detected in ZR-75-1, MCF-7 and SK-BR-3 cell lines in a previous immunohistochemistry 
study (Queiros, Preto et al. 2012). In addition, MCT3 expression was not assessed since its 
localization is specific to retinal pigment epithelium (RPE) and choroid plexus epithelia (CPE) 
(Halestrap 2012; Halestrap and Wilson 2012). The isoform MCT4 was highly expressed in ZR-75-
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1 and MDA-MB-231 as verified by Gallagher and colleagues (Gallagher, Castorino et al. 2007), 
while MCF-7 and SK-BR-3 cell lines showed low MCT4 expression as already described (Queiros, 
Preto et al. 2012). The correct targeting and anchoring of functional MCT1 and MCT4 to the 
plasma membrane depends on association with chaperone CD147 in the endoplasmatic 
reticulum (Kirk, Wilson et al. 2000; Nabeshima, Iwasaki et al. 2006; Halestrap and Wilson 
2012). Another chaperon, CD44, was also been associated to MCT plasma membrane 
localization (Slomiany, Grass et al. 2009; Pinheiro, Reis et al. 2010). Therefore, we also evaluate 
the expression profile of these ancillary proteins. CD147 was highly expressed in ZR-75-1 cell line 
that also expressed MCT4 and MCT1 isoforms, while CD44 was highly expressed in ZR-75-1 and 
MCF-7 cell lines. pH regulators systems are also involved in high glycolytic phenotype of cancer 
cells, thus we evaluated the expression of anion exchanger 1 (AE1) in all breast cancer cell lines. 
AE1 or band 3 protein was only expressed in ZR-75-1 and MCF-7. Our results indicate that the 
expression pattern of MCTs is not correlated with ER expression, although the cell line more 
aggressive SK-BR-3 (ER-) has lower expression of these transporters. Characterization of MCTs 
protein expression in isolated plasma membranes and organelles, such as mitochondria may add 
new information important to determine the distribution and localization of these transporters in 
cellular environment. Evaluation of other relevant proteins in cancer cell metabolism, such as 
HKII and GAPDH would be also important in the context of the present study giving new insights 
to understand the reasons why these different cell lines have different sensibilities to 3-BP. 
 
 
5.2. Lower dose of butyrate potentiates the effect of 3-BP in cell lines more 
sensitive 
 
The effect of butyrate alone or in combination with 3-BP on cell viability in human breast 
cancer cell lines was evaluated by Trypan Blue exclusion assay. The conventional assay MTT and 
MTS based on metabolic reduction of compounds is not so adequate when metabolism is altered 
(Mathupala, Parajuli et al. 2004; Ganapathy-Kanniappan, Geschwind et al. 2010). Trypan Blue 
exclusion assay results showed different effects on cell viability in response to butyrate alone or in 
co-incubation with 3-BP in all breast cancer cell lines. Butyrate decreased cell viability according 
to its concentration as verified by Queirós and colleagues (Queiros, Preto et al. 2012). This 
cytotoxic effect was more evident in cell lines more sensitive to 3-BP (ZR-75-1, MCF-7) and in 
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MDA-MB-231 where the lower dose of butyrate (0.5 mM) did not alter cell viability, whereas the 
highest dose (10 mM) decreased cell viability. In cells more resistant to 3-BP, SK-BR-3, butyrate 
decreased cell viability independently of dose used. The transport of anionic form of butyrate is 
mediated by MCT1 and SMCT1 (Cuff, Dyer et al. 2005; Gupta, Martin et al. 2006; Thangaraju, 
Cresci et al. 2008) and MCT1 was expressed in all breast cancer cell lines. In addition, the fact 
that butyrate can function at low levels as a histone acetyltransferase (HAT) promoter, influencing 
cell proliferation and at high levels as a histone deacetylase (HDAC) inhibitor, inducing the 
expression of genes that inhibit cell proliferation and promote apoptosis, probably explain the 
observed viability phenotypes (Donohoe, Collins et al. 2012). As verified by others in colon 
adenocarcinoma cells, butyrate can inhibit proliferation and induce cell death related to its 
function as HDAC (Hinnebusch, Meng et al. 2002). It would be interesting to evaluate the HDAC 
activity to ascertain if induction of cell death by higher dose of butyrate (10 mM) was associated 
with inhibition of HDAC in breast cancer cell lines. 
The cellular response to treatment with butyrate in combination with 3-BP showed different 
results from our previous published results, where butyrate pre-treatment sensitized SK-BR-3 
cells to 3-BP action (Queiros, Preto et al. 2012). Results of simultaneous treatment in SK-BR-3 
did not potentiates the effect of 3-BP, the differences observed may be due to the time of 
incubation (16 hours) different from our previous published results where cells were incubated 
during 24 hours in medium containing butyrate followed by 16 hours incubation in medium with 
3-BP. The fact that in our previous study were used MTT assay to determine cell viability, a not so 
adequate assay when MCT activity is altered, can also contribute to the different viability 
phenotypes observed in SK-BR-3 cell line. 
In ZR-75-1 and MCF-7 cells, more sensitive to 3-BP, cell viability was increased in response 
to simultaneous treatment of 3-BP with the highest dose of butyrate, inhibiting the cytotoxic effect 
of 3-BP. In contrast, simultaneous treatment of 3-BP with the lower dose of butyrate decreased 
cell viability contributing to the 3-BP cytotoxic effect. Others studies also demonstrated the 
synergetic effect of lower dose of butyrate (0.5 mM) and the anticancer agent cisplatin in HeLa 
cells after 1 day of treatment (Koprinarova, Markovska et al. 2010). 
In MDA-MB-231 cell line, cell viability was decreased in response to simultaneous 
treatment of 3-BP with the highest dose of butyrate, contributing to cytotoxic effect of 3-BP. The 
mechanism for the entry of 3-BP and anionic form of butyrate involves MCT1 (Cuff, Dyer et al. 
2005; Birsoy, Wang et al. 2013), the affinity of substrates for MCT1, may be explain these 
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results. Complemented radioactivity studies with 3-BP and butyrate radiolabelled would be 
important to explore these results based on entry of 3-BP and butyrate into cancer cells. 
 
 
5.3.  3-BP induces MCT2 expression in cell lines more sensitive 
 
We hypothesized that butyrate possibly regulate the expression of monocarboxylate 
transporters in co-treatment with 3-BP contributing to its cytotoxicity effect. In order to explore the 
different viability phenotypes observed, MCTs expression was assessed by western blot in all cell 
lines upon carboxylic acid treatment. We observed that 3-BP increased the expression of MCT2 in 
the most sensitive cell lines, ZR-75-1 and MCF-7 and moreover, the high expression of MCT2 was 
also detected in co-treatment with the lower dose of butyrate but not with the higher dose. 
In ZR-75-1, treatment with 3-BP alone or in combination with the lower dose of butyrate 
(0.5 mM) increased the expression of MCT1, MCT2 and MCT4, while in combination with the 
higher dose decreased the expression of these MCTs isoforms. Maintenance of MCTs expression 
pattern upon treatment with 3-BP alone or in combination with a lower dose of butyrate could be 
related to the cytotoxic effect on cell viability described. MCT2 catalyzes with higher affinity the 
uptake of lactate and pyruvate in gluconeogenic cells such localized in brain and liver (Halestrap 
and Meredith 2004). The upregulation of MCT2 by 3-BP suggests that this MCT isoform could 
have an important function some organelle membranes. McClelland and colleagues 
demonstrated a possible role of MCT2 in hepatocyte peroxisomal membrane (McClelland, 
Khanna et al. 2003). Evaluation of the MCT2 localization in the cell by immunocytochemistry or 
analysis of protein expression in isolated organelles membranes by western blot would be 
necessary to determine the involvement of this MCT isoform in 3-BP cytotoxic effect. 
In MCF-7 cell line, treatment with higher dose of butyrate decreased the expression of 
MCT4. In contrast treatment with butyrate alone or in combination with 3-BP increased the 
expression of MCT4 but not MCT1 in MDA-MB-231 cell line. In more resistant cells SK-BR-3, the 
expression of MCT1, MCT2 and MCT4 was not induced by 3-BP and lower doses of butyrate (0.5 
mM) alone or in combination with 3-BP induced the expression of MCT4 but not MCT1 as 
previous verified by us in immunohistochemistry studies (Queiros, Preto et al. 2012). The affinity 
of butyrate and 3-BP to MCT1 could explain the different phenotype observed with low and high 
dose of butyrate. 
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5.4.  3-BP reduces the amount of actin in most sensitive cell line 
 
 In this work, actin protein was not detected by western blot upon 3-BP treatment in the cell 
lines more sensitive to 3-BP, ZR-75-1 and MCF-7. Therefore, we investigated if 3-BP could induce 
alterations in actin structure by fluorescence microscopy using Alexa Fluor 488 Phalloidin, a 
fluorescent probe with high affinity to filamentous actin (F-actin). Our preliminary results showed 
that 3-BP reduced the amount of actin in ZR-75-1 but not in the most resistant cell line, SK-BR-3. 
Moreover, the shape of ZR-75-1 but not SK-BR-3 cells was also altered from elongate to round 
cells. F-actin cytoskeleton lost its stress fibers and adopted a more rounded morphology, after 16 
hours of treatment with 3-BP in ZR-75-1 cell line. These results could suggest that 3-BP action 
also affects actin dynamics recently associated with the phenomenon termed anoikis, 
characterized by loss of attachment to the extracellular matrix and consequent apoptosis (Frisch 
and Screaton 2001). Cancer cells resistant to anoikis after cell detachment which contributes to 
metastasis allowing cancer cells invade distant sites (Simpson, Anyiwe et al. 2008). This 
resistance is promoted by activation of survival pathways such as induced by PI3K signaling and 
HIF-1, also important in maintenance of glycolysis (Rohwer, Welzel et al. 2008). Recent study 
showed that treatment with an inhibitor of histone deacetylase activity (HDAC), SAHA, restores 
sensitivity to anoikis in MDA-MB-231 breast cancer cells (Lauricella, Ciraolo et al. 2011). Our 
preliminary results suggest that 3-BP could induce cell death by anoikis in more sensitive cell line 
ZR-75-1. However, these results need further confirmation, as well as validation through a anoikis 
assay to ascertain if 3-BP induced cell death in ZR-75-1 by this apoptotic pathway, such a cell 
detachment assay in a poly-HEMA-coated plates. Invasion and migration are important 
mechanisms in tumor progression allowing cancer cells to escape from primary tumor and 
colonize other regions (Hanahan and Weinberg 2011). Evaluate the influence of 3-BP in 
migration and invasion capacity by wound-healing assay and matrigel invasion assay, would be 
also important to explore the mechanism of action of this anticancer drug. 
 
 
5.5. Optimization of RNAi conditions for MCT1 and MCT4 silencing 
 
In order to explore the role of MCTs in butyrate and 3-BP cytotoxic effect, the conditions for 
MCT1 and MCT4 silencing by RNA interference (RNAi) were optimized in ZR-75-1, MCF-7 and SK-
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BR-3 cell lines. The transfection conditions were not optimized for MDA-MB-231 cell line since the 
inhibition of MCT4 expression by RNAi is described in the literature (Gallagher, Castorino et al. 
2007). Transfection reagent Lipofectamine RNAiMAX was efficient in delivery exogenous 
fluorescent non-target siRNA (siRNA-AF) with low cytotoxicity in all cell lines after four days of 
transfection. In ZR-75-1 and MCF-7 cell lines, 1 μl of Lipofectamine RNAiMAX presented more 
internalization of siRNA-AF. Moreover, in SK-BR-3, 2 μl of Lipofectamine RNAiMAX was more 
efficient in cellular delivery of siRNA-AF. The amount of specific siRNA target MCT1 and MCT4 
and time point were also optimized for ZR-75-1 and SK-BR-3 cell lines. In ZR-75-1 cell line, 
inhibition of MCT4 and MCT1 expression with both 5 nM and 10 nM siRNA target resulted in very 
lower silencing of the two proteins after 4 and 5 days of transfection. In SK-BR-3, the 
transfections showed inefficient in specific MCT1 silencing since transfection with non-silencing 
siRNA resulted in downregulation of MCT1 expression. In fact, the transfection with non-silencing 
siRNA was used as a control of transfection, and since this sequence is not specific for silencing 
MCT1 mRNA the results of silencing of MCT1 by transfection with siRNA target MCT1 could be 
induced by deregulation of transcription. The inhibition of MCT4 expression with 5 nM and 10 nM 
siRNA target MCT4 resulted in approximately 70% reduction of protein expression in SK-BR-3 cell 
line. It would be important to evaluate changes in MCT1 and MCT4 mRNA levels after target 
silencing by RT-PCR, to confirm silencing. In addition, it would be also interesting to performe 
also MCTs activity inhibition with specific inhibitors of MCTs such as developed by AstraZeneca to 
ascertain the involvement of MCTs activity in butyrate and 3-BP cytotoxic effect.  
 
 
5.6. Highest dose of butyrate increases the number of cells on G1 phase in MDA-
MB-231 cell line 
 
To evaluate the effect of butyrate alone or in combination with 3-BP on cell cycle, a flow 
cytometry analysis by measuring the DNA content of cells was performed. 
Cell cycle is a series of ordered events that leads to cell’s division and duplication. These 
events comprise interphase, mitosis and cytokinesis. The interphase consist in three phases, 
where G1 phase (Gap 1) is responsible for cell growth, mRNA and proteins synthesis required for 
DNA replication, S phase (DNA synthesis) in which DNA replicates followed by G2 phase (Gap 2) 
wherein cell prepares to divide in mitosis process. After interphase, cell cycle proceeds to mitotic 
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phase defined by mitosis and cytokinesis. Mitosis (M phase) is the nuclear division and 
comprises prophase, metaphase, anaphase and telophase and the cytokinesis is the 
cytoplasmatic division. Cell cycle analysis performed by flow cytometry using propidium iodide 
(PI), a fluorescent dye that intercalates DNA allowing a precise measurement of DNA content of 
cells in different phases of interphase, including sub-G1 assumed as death cells. 
In the present work, the highest dose of butyrate (10 mM) alone or in co-incubation with 3-
BP IC50 increased the percentage of cells in G1 phase, in MDA-MB-231 cells. In fact, other study 
showed that 10 mM of butyrate affects cell cycle at very early stage of G1 phase in Madin Darby 
Bovine Kidney cells (MDBK) (Li 2011). Moreover, 10 mM butyrate alone or in combination with 
3-BP increased the percentage of cells with sub-G1 DNA content may be due to the DNA 
fragmentation in death cells suggesting that apoptosis might occur. The flow cytometry analysis 
confirmed the results of trypan blue exclusion assay. However, more studies are need to better 
understand the role of butyrate alone or in combination with 3-BP in MDA-MB-231 cell cycle 
since these results were obtained from a single experiment. Concerning the other cell lines 
higher percentage of cells with sub-G1 DNA content without acid treatment were observed, not 
being possible to distinguish the cell cycle phases G1, S and G2 in the monoparametric 
histograms of DNA. The fact that adherent cells need to be trypsinized or scraped to prepare 
individual cells in suspension to be analyzed by flow cytometry, promote loss of membrane 
integrity and consequent entry of PI into the cells. It would be necessary to optimize this critical 
point of protocol and cytometer parameters as intensity of fluorescence (FL-3 channel (488/620 
nm)) to ascertain the effect of butyrate and 3-BP in ZR-75-1, MCF-7 and SK-BR-3 cell lines on cell 
cycle. Additional assays, such as Annexin/PI assay, western blot analysis of activated caspase-3, 
or TUNEL assay indicative of apoptosis, would be necessary to determine which type of cell death 
is being triggered: apoptosis or necrosis. 
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Carcinogenesis is a multistage process marked by the reprograming of cellular energy 
metabolism of cancer cells (Hanahan and Weinberg 2011). MCTs are key players in high 
glycolytic metabolism and acid resistant phenotype allowing the efflux of formed lactate couple to 
the output of a proton (Chiche, Brahimi-Horn et al. 2010). 3-BP is pyruvate analogue, and an 
alkylating agent able to inhibit the energetics of cancer cells (Ko, Pedersen et al. 2001). In the 
present study we intent elucidated the mechanism of 3-BP action in the presence of a 
monocarboxylic acid butyrate. Our observations indicated that four human breast cancer cell 
lines presented a distinct basal expression pattern of MCTs and ancillary proteins important to 
their function. The different expression of MCTs should be taken into account given the 
importance of these transporters in the selective effect of 3-BP. 
Our results showed that lower dose of butyrate contribute to cytotoxic effect of 3-BP, while 
the high dose led to an inhibition effect in the more sensitive human breast cancer cell lines, ZR-
75-1 and MCF-7. In addition, we also found that 3-BP alone or in combination with the lower 
dose of butyrate induced the expression of MCT2 in ZR-75-1 and MCF-7. Understanding the role 
of MCTs in 3-BP cytotoxic effect may be a starting point to uncover selective process of 3-BP 
uptake into cancer cells. Thus, we started to optimize the conditions for siRNA-mediated silencing 
of MCT1 and MCT4 expression in breast cancer cell lines to explore the results. 
In this work we also observed that 3-BP induced alteration in actin structure in ZR-75-1, 
feature associated to cell death induced by anoikis. However, for the complete understanding of 
this mechanism additionally experiments are necessary. Other important question that needs to 
be answered is the effect of 3-BP alone or in combination with butyrate in non-tumorigenic 
human mammary epithelial cells, such as in MCF-10A cell line. It would be also interesting to 
study the effect of 3-BP in animal breast cancer models (e. g. mice) since in vitro studies do not 
mimic all tumor conditions. 
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